US20050139489A1 - Method of reducing the effect of direct and mediated interference current in an electrochemical test strip - Google Patents
Method of reducing the effect of direct and mediated interference current in an electrochemical test strip Download PDFInfo
- Publication number
- US20050139489A1 US20050139489A1 US10/977,086 US97708604A US2005139489A1 US 20050139489 A1 US20050139489 A1 US 20050139489A1 US 97708604 A US97708604 A US 97708604A US 2005139489 A1 US2005139489 A1 US 2005139489A1
- Authority
- US
- United States
- Prior art keywords
- working electrode
- reagent layer
- inactive
- active
- test strip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 230000000694 effects Effects 0.000 title description 27
- 230000001404 mediated effect Effects 0.000 title description 6
- 238000000840 electrochemical analysis Methods 0.000 title description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 91
- 239000012042 active reagent Substances 0.000 claims abstract description 82
- 239000008103 glucose Substances 0.000 claims abstract description 77
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 76
- 239000010410 layer Substances 0.000 description 209
- 238000012360 testing method Methods 0.000 description 133
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 70
- 230000003647 oxidation Effects 0.000 description 50
- 238000007254 oxidation reaction Methods 0.000 description 50
- 108090000790 Enzymes Proteins 0.000 description 36
- 102000004190 Enzymes Human genes 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 36
- 229940088598 enzyme Drugs 0.000 description 36
- 230000002452 interceptive effect Effects 0.000 description 36
- 238000009413 insulation Methods 0.000 description 19
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 18
- 230000005855 radiation Effects 0.000 description 16
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 10
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 9
- 239000012790 adhesive layer Substances 0.000 description 9
- 238000012937 correction Methods 0.000 description 9
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 9
- 229960005219 gentisic acid Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 229940116269 uric acid Drugs 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000007639 printing Methods 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 6
- 238000007650 screen-printing Methods 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- -1 for example Chemical class 0.000 description 5
- 230000005865 ionizing radiation Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010015776 Glucose oxidase Proteins 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229940116332 glucose oxidase Drugs 0.000 description 4
- 235000019420 glucose oxidase Nutrition 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010894 electron beam technology Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical class Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- KXVGTQFNYXBBHD-UHFFFAOYSA-N ethenyl acetate;pyrrolidin-2-one Chemical compound CC(=O)OC=C.O=C1CCCN1 KXVGTQFNYXBBHD-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 150000002907 osmium Chemical class 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000012777 electrically insulating material Substances 0.000 description 1
- 238000007772 electroless plating Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical class [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000004059 quinone derivatives Chemical class 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 238000012776 robust process Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/49—Systems involving the determination of the current at a single specific value, or small range of values, of applied voltage for producing selective measurement of one or more particular ionic species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/150022—Source of blood for capillary blood or interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150274—Manufacture or production processes or steps for blood sampling devices
- A61B5/150282—Manufacture or production processes or steps for blood sampling devices for piercing elements, e.g. blade, lancet, canula, needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150358—Strips for collecting blood, e.g. absorbent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150412—Pointed piercing elements, e.g. needles, lancets for piercing the skin
- A61B5/150435—Specific design of proximal end
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150503—Single-ended needles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
- C12Q1/006—Enzyme electrodes involving specific analytes or enzymes for glucose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3274—Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Definitions
- an electrochemical glucose measuring system may have an elevated oxidation current due to the oxidation of interfering compounds commonly found in physiological fluids such as, for example, acetaminophen, ascorbic acid, bilirubin, dopamine, gentisic acid, glutathione, levodopa, methyldopa, tolazimide, tolbutamide, and uric acid.
- the accuracy of glucose meters may, therefore, be improved by reducing or eliminating the portion of the oxidation current generated by interfering compounds.
- there should be no oxidation current generated from any of the interfering compounds so that the entire oxidation current would depend only on the glucose concentration.
- the present invention is further directed to a method of reducing interferences in an electrochemical sensor wherein the method includes the step of measuring a first current at a first working electrode, the first working electrode being covered by an active reagent layer, the step of measuring a second current at a second working electrode, wherein the active reagent layer is disposed on an active region of the second working electrode and an inactive region of the second working electrode is covered by an inactive reagent layer and the step of calculating a corrected current value representative of a glucose concentration using a ratio of an active region on the first and second working electrodes and an inactive region on the second working electrode.
- FIG. 11 is a graph showing the effects of gamma radiation on precision for test strips tested at a 20 mg/dL glucose concentration
- FIG. 12 is a graph showing the effects of gamma radiation on precision for test strips tested at a 50 mg/dL glucose concentration
- FIG. 1 shows an exploded perspective view of a test strip 800 that is designed to compensate for the variations in increased background potentially caused by the conversion of oxidized mediator to reduced mediator.
- an electrochemical test strip 800 which may be used for measuring glucose concentration in bodily fluids such as blood or interstitial fluid, includes a first working electrode 808 , a second working electrode 806 , and a reference electrode 810 .
- An active reagent layer 820 is disposed on first working electrode 808 and reference electrode 810 where active reagent layer 820 completely covers first working electrode 808 and at least partially covers reference electrode 810 .
- An inactive reagent layer 818 is disposed on second working electrode 806 .
- inactive reagent layer 818 will also cause inactive reagent layer 818 to sometimes not touch active reagent layer 820 . Because inactive reagent layer 818 was allowed to touch or not touch active reagent layer 820 and the operation of the method of the invention still works to reduce the variation in the background in either circumstance, the yield of acceptable test strips was improved.
- test cases which are Batch 1 —0 kGy, Batch 1 —25 kGy, Batch 2 —0 kGy, and Batch 2 —25 kGy, were evaluated for precision by testing 24 test strips with blood for each test case at 5 glucose concentrations which was 20, 50, 100, 300, and 500 mg/dL.
- Batch 3 Another batch of test strips, which is referred to as Batch 3 , was prepared in a manner similar to test strip 800 except that second working electrode 806 was not coated with either active reagent layer 820 or inactive reagent layer 818 .
- Batches 1 to 3 were tested to evaluate the overall accuracy in the presence of interfering compounds such as uric acid and gentisic acid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Optics & Photonics (AREA)
- Manufacturing & Machinery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Electrochemistry (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
Abstract
The present invention is directed to a method of reducing interferences in an electrochemical sensor wherein the method includes the step of measuring a first current at a first working electrode, the first working electrode being covered by an active reagent layer, the step of measuring a second current at a second working electrode, the second working electrode being covered by an inactive reagent layer and the step of calculating a corrected current value representative of a glucose concentration using a ratio of an active area of the first working electrode to an inactive area of the second working electrode. The present invention is further directed to a method of reducing interferences in an electrochemical sensor wherein the method includes the step of measuring a first current at a first working electrode, the first working electrode being covered by an active reagent layer, the step of measuring a second current at a second working electrode, wherein the active reagent layer is disposed on an active region of the second working electrode and an inactive region of the second working electrode is covered by an inactive reagent layer and the step of calculating a corrected current value representative of a glucose concentration using a ratio of an active region on the first and second working electrodes and an inactive region on the second working electrode.
Description
- The present invention claims priority to the following US Provisional Applications: U.S. Provisional Application Ser. No. 60/516,252 filed on Oct. 31, 2003; U.S. Provisional Application Ser. No. 60/558,424 filed on Mar. 31, 2004; and U.S. Provisional Application Ser. No. 60/558,728 filed on Mar. 31, 2004. Which applications are hereby incorporated herein by reference.
- The present invention is related to the following co-pending US applications: U.S. patent application Ser. No. ______ [Attorney Docket Number DDI-5027 USNP], filed on Oct. 29, 2004; U.S. patent application Ser. No. ______ [Attorney Docket Number DDI-5042 USNP], filed on Oct. 29, 2004; U.S. patent application Ser. No. ______ [Attorney Docket Number DDI-5064], filed on Oct. 29, 2004; U.S. patent application Ser. No. ______ [Attorney Docket Number DDI-5065], filed on Oct. 29, 2004; and U.S. patent application Ser. No. ______ [Attorney Docket Number DDI-5066], filed on Oct. 29, 2004.
- The present invention is related, in general to methods of reducing the effect of interfering compounds on measurements taken by analyte measurement systems and, more particularly, to a method of reducing the effects of direct interference currents and mediated interference currents in a glucose monitoring system using an electrochemical strip having electrodes with regions coated with active reagent and regions coated with inactive reagent.
- In many cases, an electrochemical glucose measuring system may have an elevated oxidation current due to the oxidation of interfering compounds commonly found in physiological fluids such as, for example, acetaminophen, ascorbic acid, bilirubin, dopamine, gentisic acid, glutathione, levodopa, methyldopa, tolazimide, tolbutamide, and uric acid. The accuracy of glucose meters may, therefore, be improved by reducing or eliminating the portion of the oxidation current generated by interfering compounds. Ideally, there should be no oxidation current generated from any of the interfering compounds so that the entire oxidation current would depend only on the glucose concentration.
- It is, therefore, desirable to improve the accuracy of electrochemical sensors in the presence of potentially interfering compounds such as, for example, ascorbate, urate, and, acetaminophen, commonly found in physiological fluids. Examples of analytes for such electrochemical sensors may include glucose, lactate, and fructosamine. Although glucose will be the main analyte discussed, it will be obvious to one skilled in the art that the invention set forth herein may also be used with other analytes.
- Oxidation current may be generated in several ways. In particular, desirable oxidation current results from the interaction of the mediator with the analyte of interest (e.g., glucose) while undesirable oxidation current is generally comprised of interfering compounds being oxidized at the electrode surface and by interaction with the mediator. For example, some interfering compounds (e.g., acetominophen) are oxidized at the electrode surface. Other interfering compounds (e.g., ascorbic acid) are oxidized by chemical reaction with the mediator. This oxidation of the interfering compound in a glucose measuring system causes the measured oxidation current to be dependent on the concentration of both the glucose and any interfering compound. Therefore, in the situation where the concentration of interfering compound oxidizes as efficiently as glucose and the interferent concentration is high relative to the glucose concentration, the measurement of the glucose concentration would be improved by reducing or eliminating the contribution of the interfering compounds to the total oxidation current.
- One known strategy that can be used to decrease the effects of interfering compounds is to use a negatively charged membrane to cover the working electrode. As an example, a sulfonated fluoropolymer such as NAFION™ may be used to repel all negatively charged chemicals. In general, most interfering compounds such as ascorbate and urate have a negative charge, thus, the negatively charged membrane prevents the negatively charged interfering compounds from reaching the electrode surface and being oxidized at that surface. However, this technique is not always successful since some interfering compounds such as acetaminophen do not have a net negative charge, and thus, can pass through a negatively charged membrane. Nor would this technique reduce the oxidation current resulting from the interaction of interfering compounds with some mediators. The use of a negatively charged membrane on the working electrode could also prevent some commonly used mediators, such as ferricyanide, from passing through the negatively charged membrane to exchange electrons with the electrode.
- Another known strategy that can be used to decrease the effects of interfering compounds is to use a size selective membrane on top of the working electrode. As an example, a 100 Dalton exclusion membrane such as cellulose acetate may be used to cover the working electrode to exclude all chemicals with a molecular weight greater than 100 Daltons. In general, most interfering compounds have a molecular weight greater than 100 Daltons, and thus, are excluded from being oxidized at the electrode surface. However, such selective membranes typically make the test strip more complicated to manufacture and increase the test time because the oxidized glucose must diffuse through the selective membrane to get to the electrode.
- Another strategy that can be used to decrease the effects of interfering compounds is to use a mediator with a low redox potential, for example, between about −300 mV and +100 mV (when measured with respect to a saturated calomel electrode). Because the mediator has a low redox potential, the voltage applied to the working electrode may also be relatively low which, in turn, decreases the rate at which interfering compounds are oxidized by the working electrode. Examples of mediators having a relatively low redox potential include osmium bipyridyl complexes, ferrocene derivatives, and quinone derivatives. A disadvantage of this strategy is that mediators having a relatively low potential are often difficult to synthesize, unstable and have a low water solubility.
- Another known strategy that can be used to decrease the effects of interfering compounds is to use a dummy electrode which is coated with a mediator. In some instances the dummy electrode may also be coated with an inert protein or deactivated redox enzyme. The purpose of the dummy electrode is to oxidize the interfering compound at the electrode surface and/or to oxidize the mediator reduced by the interfering compound. In this strategy, the current measured at the dummy electrode is subtracted from the total oxidizing current measured at the working electrode to remove the interference effect. A disadvantage of this strategy is that it requires that the test strip include an additional electrode and electrical connection (i.e., the dummy electrode) which cannot be used to measure glucose. The inclusion of dummy electrode is an inefficient use of an electrode in a glucose measuring system.
- The present invention is directed to a method of reducing interferences in an electrochemical sensor wherein the method includes the step of measuring a first current at a first working electrode, the first working electrode being covered by an active reagent layer, the step of measuring a second current at a second working electrode, the second working electrode being covered by an inactive reagent layer and the step of calculating a corrected current value representative of a glucose concentration using a ratio of an active area of the first working electrode to an inactive area of the second working electrode.
- The present invention is further directed to a method of reducing interferences in an electrochemical sensor wherein the method includes the step of measuring a first current at a first working electrode, the first working electrode being covered by an active reagent layer, the step of measuring a second current at a second working electrode, wherein the active reagent layer is disposed on an active region of the second working electrode and an inactive region of the second working electrode is covered by an inactive reagent layer and the step of calculating a corrected current value representative of a glucose concentration using a ratio of an active region on the first and second working electrodes and an inactive region on the second working electrode.
- A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings, of which:
-
FIG. 1 is an exploded perspective view of a test strip according to an exemplary embodiment of the present invention; -
FIG. 2 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 1 including a conductive layer and an insulation layer; -
FIG. 3 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 1 , wherein the position of an active and an inactive reagent layer do not touch each other and are illustrated with the insulation and conductive layer; -
FIG. 4 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 1 , wherein the position of the active and the inactive reagent layer are immediately adjacent to each other and are illustrated with the insulation and conductive layer; -
FIG. 5 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 1 , wherein the position of the active and the inactive reagent layer that overlap with each other and are illustrated with the insulation and conductive layer; -
FIG. 6 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 1 , wherein the active and the inactive reagent layer do not touch each other and are illustrated with the conductive layer; -
FIG. 7 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 1 , wherein the active and the inactive reagent layer are immediately adjacent to each other and are illustrated with the conductive layer; -
FIG. 8 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 1 , wherein the active and the inactive reagent layer overlap with each other and are illustrated with the conductive layer; -
FIG. 9 is a simplified schematic showing a meter interfacing with a test strip that has a first contact, second contact, and reference contact disposed on a substrate; -
FIG. 10 is a simplified schematic showing a meter interfacing with a test strip that has a first contact and a second contact disposed on a substrate and a reference contact which is orientated in a facing orientation with the first contact and second contact; -
FIG. 11 is a graph showing the effects of gamma radiation on precision for test strips tested at a 20 mg/dL glucose concentration; -
FIG. 12 is a graph showing the effects of gamma radiation on precision for test strips tested at a 50 mg/dL glucose concentration; -
FIG. 13 is a graph showing the effects of gamma radiation on precision for test strips tested at a 100 mg/dL glucose concentration; -
FIG. 14 is a graph showing the effects of gamma radiation on precision for test strips tested at a 300 mg/dL glucose concentration; -
FIG. 15 is a graph showing the effects of gamma radiation on precision for test strips tested at a 500 mg/dL glucose concentration; -
FIG. 16 is a graph showing the effects of gentisic acid on accuracy for test strips tested at a 70 mg/dL glucose concentration; -
FIG. 17 is a graph showing the effects of gentisic acid on accuracy for test strips tested at a 240 mg/dL glucose concentration; -
FIG. 18 is a graph showing the effects of uric acid on accuracy for test strips tested at a 70 mg/dL glucose concentration; -
FIG. 19 is a graph showing the effects of uric acid on accuracy for test strips tested at a 240 mg/dL glucose concentration; -
FIG. 20 a simplified plane view of a distal portion of a test showing a modified cutout that allows the area of a second working electrode to be increased; -
FIG. 21 is an exploded perspective view of a test strip according to another exemplary embodiment of the present invention; -
FIG. 22 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 21 , wherein the position of an active and an inactive reagent layer do not touch each other and are illustrated with the insulation and conductive layer; -
FIG. 23 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 21 , wherein the position of the active and the inactive reagent layer are immediately adjacent to each other and are illustrated with the insulation and conductive layer; -
FIG. 24 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 21 , wherein the position of the active and the inactive reagent layer that overlap with each other and are illustrated with the insulation and conductive layer; -
FIG. 25 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 21 , wherein the active and the inactive reagent layer do not touch each other and are illustrated with the conductive layer; -
FIG. 26 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 21 , wherein the active and the inactive reagent layer are immediately adjacent to each other and are illustrated with the conductive layer; and -
FIG. 27 is a simplified plane view of a distal portion of a test strip according to the embodiment of the present invention illustrated inFIG. 21 , wherein the active and the inactive reagent layer overlap with each other and are illustrated with the conductive layer; - The invention described herein includes a test strip to improve the accuracy of a glucose measurement in the presence of interfering compounds. Under certain circumstances, a type of interfering compound may develop in the test strip itself before bodily fluid such as, for example, blood is added. An example this type of interfering compound may be a reduced mediator (e.g. ferrocyanide) which develops from the conversion of an oxidized mediator (e.g. ferricyanide). This causes the background signal to increase which, in turn, decreases the accuracy of the test strip measurement. It should be noted that in this circumstance the interfering compound develops in the test strip itself as opposed to being provided to the test strip in the form of a bodily fluid.
- Typically, an oxidized mediator is disposed on a working electrode with the intent that the oxidized mediator will be stable and not transition over to the reduced redox state. The generation of reduced mediator causes the background signal to increase for electrochemical sensors which use an oxidation current to correlate with the glucose concentration. In general, ferricyanide (e.g. oxidized mediator) tends to become reduced over time to the reduced redox state. Ferricyanide generally transitions to the reduced redox state more rapidly when exposed to environmental conditions which include but are not limited to, basic pH, elevated temperature, elevated humidity, bright light conditions, electron beam radiation, and gamma radiation.
- Recently, a lance and a test strip have been integrated into a single medical device. These integrated medical devices can be employed, along with an associated meter, to monitor various analytes, including glucose. Depending on the situation, test strips can be designed to monitor analytes in an episodic single-use format, semi-continuous format, or continuous format. The integration of the lance and the test strip simplifies a monitoring procedure by eliminating the need for a user to coordinate the extraction of a bodily fluid from a sample site with the subsequent transfer of that bodily fluid to the test strip. In such a case, the lance and test strip must be sterilized together so as to mitigate the risk of infection.
- Ionizing radiation may be used to sterilize test strips with a lance. Possible sources of ionizing radiation are electron beam, gamma, and x-ray. However, one of the challenges in sterilizing a test strip is to provide a sufficiently high intensity of radiation such that a sufficiently high proportion of microorganisms are neutralized for an entire package of test strips, while at the same time not adversely affecting the reagent layer. Typically, a batch or package of test strips are exposed to an ionizing radiation dose ranging from about 10 KGy to about 50 KGy. For the case using e-beam sterilization, the energy of the incident e-beam source can range from about 3 MeV to about 12 MeV. The impingent ionizing radiation may often have some non-uniformities in its intensity causing a particular portion of the package to receive more ionizing radiation than another portion of the package. Experiments have shown that both gamma radiation and electron beam radiation cause the background signal of the electrochemical sensors to increase. Furthermore, the relatively non-uniform nature of the radiation causes the background signal to increase in a non-uniform nature for a sterilized batch of test strips. This causes the precision to decrease when testing a particular batch of sterilized glucose test strips. In addition, the decrease in precision is exacerbated at the low glucose concentration range (e.g. about 20 mg/dL to about 100 mg/dL) because the proportion of reduced mediator is relatively high with respect to the low glucose concentration range.
-
FIG. 1 shows an exploded perspective view of atest strip 800 that is designed to compensate for the variations in increased background potentially caused by the conversion of oxidized mediator to reduced mediator. In the embodiment of the present invention illustrated inFIG. 1 , anelectrochemical test strip 800, which may be used for measuring glucose concentration in bodily fluids such as blood or interstitial fluid, includes a first workingelectrode 808, asecond working electrode 806, and areference electrode 810. Anactive reagent layer 820 is disposed on first workingelectrode 808 andreference electrode 810 whereactive reagent layer 820 completely covers first workingelectrode 808 and at least partially coversreference electrode 810. Aninactive reagent layer 818 is disposed on second workingelectrode 806. - In an embodiment of this invention,
active reagent layer 820 may include, for example, glucose oxidase and a mediator such as, for example, ferricyanide.Inactive reagent layer 818 may include a mediator, but no active enzymes which are specific for the analyte of interest. Because ferricyanide has a redox potential of approximately 400 mV (when measured with respect to a saturated calomel electrode) at a carbon electrode, the introduction of a bodily fluid e.g., blood may generate a significant and undesirable oxidation of interferents by the mediator and/or the working electrode. Therefore, the oxidation current measured at first workingelectrode 808 will be a superposition of oxidation current sources: a first, desirable, oxidation current generated by the oxidation of glucose; a second, undesirable, direct oxidation of interferents at the electrode (direct interference current); and a third, undesirable, indirect oxidation of interferents via a mediator (mediated interference current). The oxidation current measured at second workingelectrode 806 will also be a superposition of oxidation current sources similar to first workingelectrode 808, but the first, desirable, oxidation current should not occur because there is no enzyme present on second workingelectrode 806. Because the oxidation current measured at second workingelectrode 806 depends only on interferents, and the oxidation current measured at first workingelectrode 808 depends on glucose and interferents, it is possible to calculate a corrected glucose current which is independent to the effects of interfering compounds oxidized at first workingelectrode 808 and second workingelectrode 806. In such a case, the current density of first workingelectrode 808 is subtracted from the current density of the second workingelectrode 806 to calculate a corrected glucose current density G where
G=WE 1 −WE 2 (Eq 8)
where WE1 is the current density at first workingelectrode 808 and WE2 is the current density at second workingelectrode 806. - In an alternative embodiment to this invention, the interferent oxidation current density at second working
electrode 806 may be slightly different than the interferent oxidation current density at first workingelectrode 808 because there is no enzyme on second workingelectrode 806. In such a case, a constant K can be used to correct for such non-idealities in the correction method. Equation 9 shows how constant K would modify the previously describedEquation 8.
G=WE 1−(K×WE 2) (Eq 9)
where K can range from about 0.5 to about 1.5. -
Test strip 800 includes asubstrate 50, aconductive layer 802, aninsulation layer 804,inactive reagent layer 818,active reagent layer 820, anadhesive layer 830, and atop layer 824.Test strip 800 may be manufactured by sequentially printing five layers which areconductive layer 802,insulation layer 804,inactive reagent layer 818,active reagent layer 820, andadhesive layer 830 ontosubstrate 50.Top layer 824 may be assembled by a lamination process.Test strip 800 further includes afirst side 54, asecond side 56, adistal portion 58, and aproximal portion 60. - In one embodiment of the present invention,
substrate 50 is an electrically insulating material such as plastic, glass, ceramic, and the like. In an embodiment of this invention,substrate 50 may be a plastic such as, for example, nylon, polycarbonate, polyimide, polyvinylchloride, polyethylene, polypropylene, PETG, or polyester. More particularly the polyester may be, for example Melinex® ST328 which is manufactured by DuPont Teijin Films.Substrate 50 may also include an acrylic coating which is applied to one or both sides to improve ink adhesion. - The first layer deposited on
substrate 50 isconductive layer 802 which includes first workingelectrode 808, second workingelectrode 806,reference electrode 810, andstrip detection bar 17. In accordance with the present invention, a screen mesh with an emulsion pattern may be used to deposit a material such as, for example, a conductive carbon ink in a defined geometry as illustrated inFIG. 1 .Conductive layer 802 may be disposed onsubstrate 50 by using screen printing, rotogravure printing, sputtering, evaporation, electroless plating, ink jetting, sublimation, chemical vapor deposition, and the like. Suitable materials which may be used forconductive layer 802 are Au, Pd, Ir, Pt, Rh, stainless steel, doped tin oxide, carbon, and the like. In an embodiment of this invention, the carbon ink layer may have a height between 1 and 100 microns, more particularly between 5 and 25 microns, and yet even more particularly at approximately 13 microns. The height ofconductive layer 802 can vary depending on the desired resistance and conductivity of the printed material. - A
first contact 814, asecond contact 812, and areference contact 816 may be used to electrically interface with a meter. This allows the meter to electrically communicate to first workingelectrode 808, second workingelectrode 806, andreference electrode 810 via, respective,first contact 814,second contact 812, andreference contact 816. - The second layer deposited on
substrate 50 isinsulation layer 804.Insulation layer 804 is disposed on at least a portion ofconductive layer 802 as shown inFIGS. 1 and 2 .FIG. 2 is a simplified plane view ofdistal portion 58 oftest strip 800 which highlights the position of first workingelectrode 808, second workingelectrode 806, andreference electrode 810 with respect toinsulation layer 804.Insulation layer 804 further includes acutout 18 which may have a rectangular shaped structure as shown inFIGS. 1 and 2 .Cutout 18 exposes a portions of first workingelectrode 808, second workingelectrode 806, andreference electrode 810 which can be wetted with liquid.Cutout 18 includes a cutout width W20 and a cutout length L26. Cutout width W20 corresponds to a width of second workingelectrode 806,reference electrode 810, and first workingelectrode 808 as illustrated inFIG. 2 . In an embodiment of this invention, cutout width W20 may range from about 0.7 mm to about 1.4 mm, and cutout length L26 may range from about 0.4 mm and about 3.4 mm. - In one embodiment of the present invention, second working
electrode 806 and first workingelectrode 808 have a respective length of L20 and L21 which may be the same and range from about 0.1 mm to about 0.8 mm.Reference electrode 810 may have a length L24 which may range from about 0.2 mm to about 1.6 mm. In accordance with the present invention, electrode spacing S1 is a distance between second workingelectrode 806 andreference electrode 810; and betweenreference electrode 810 and first workingelectrode 808 which may range from about 0.2 mm to about 0.6 mm. - In an alternative embodiment of the present invention, an area of first working
electrode 808 may be different than an area of second workingelectrode 806. A ratio of first workingelectrode 808 area:second workingelectrode 806 area may range from about 1:1 to about 1:3. Under certain situations, the reduction in background can be improved by increasing the relative area of second workingelectrode 806. The area of second workingelectrode 806 may be increased by modifying the geometry of acutout 6008 as shown inFIG. 20 . -
FIG. 2 shows that strip 800 may be cut along incision line A-A′ after it is fully laminated as illustrated inFIG. 1 . In the process of cuttingtest strip 800 along incision line A-A′ as illustrated inFIG. 1 , asample inlet 52 is created in which a liquid sample can be applied fordosing test strip 800. - FIGS. 3 to 5 are a simplified plane view of
distal portion 58 oftest strip 800 according to the embodiment of the present invention illustrated inFIG. 1 , which show various positions ofactive reagent layer 820 andinactive reagent layer 818 with respect to each other. FIGS. 6 to 8, which correspond to FIGS. 3 to 5 respectively, do not showinsulation layer 804 to help demonstrate more clearly the relationship between theconductive layer 802,active reagent layer 820, andinactive reagent layer 818. -
Test strip 800 may haveinactive reagent layer 818 disposed on second workingelectrode 806 such that it completely covers second workingelectrode 806 as is illustrated in FIGS. 3 to 5. In one embodiment of this invention,inactive reagent layer 818 completely covers second workingelectrode 806, but does not touchreference electrode 810 as is illustrated inFIGS. 3 and 4 . In another embodiment of this invention,inactive reagent layer 818 completely covers second workingelectrode 806 and at least partially coversreference electrode 810 as is illustrated inFIG. 5 . - In an embodiment of this invention,
inactive reagent layer 818 includes at least an oxidized mediator, such as ferricyanide, and may optionally include an inert protein or inactivated enzyme.Inactive reagent layer 818 may further include a citrate buffer atpH 6, a polyvinyl alcohol, a polyvinyl pyrrolidone-vinyl acetate, a Dow Corning DC1500 antifoam, a hydroxyethyl cellulose (Natrosol 250G, Hercules), and a surface modified silica (Cab-o-sil TS 610, Cabot) having both hydrophilic and hydrophobic domains. Examples of oxidized mediators may be ferricyanide, ferricinium complexes, quinone complexes, and osmium complexes. Examples of inert protein may be crotein or albumin (e.g. bovine or human). Examples of inactivated enzyme may be the apo form of PQQ-glucose dehydrogenase (where PQQ is an acronym for pyrrolo-quinoline-quinone) or apo glucose oxidase (e.g. enzyme with no active site). Enzyme may also be deactivated or sufficiently attenuated by heat treatment or by treatment with denaturing agents such as urea. Becauseinactive reagent layer 818 does not include an active enzyme, the oxidation current measured at second workingelectrode 806 is not proportional to the glucose concentration. For this reason, one skilled in the art may refer to second workingelectrode 806 as a dummy electrode. - In an embodiment of this invention, the inert protein or deactivated enzyme in
inactive reagent layer 818 may act as a stabilizer for the mediator. The inert protein or deactivated enzyme may shield the mediator during the drying process at elevated temperature. In addition, the inert protein or deactivated enzyme may act as a desiccant which helps protect the mediator from moisture that may potentially destabilize the mediator. -
Test strip 800 hasactive reagent layer 820 disposed on first workingelectrode 808 as illustrated in FIGS. 3 to 5. In another embodiment of this invention,active reagent layer 820 completely covers first workingelectrode 808, but does not touchreference electrode 810. In another embodiment of this invention,active reagent layer 820 completely covers first workingelectrode 808 and at least partially coversreference electrode 810 as illustrated in FIGS. 3 to 5. - In an embodiment of this invention,
active reagent layer 820 includes at least an oxidized mediator, and an enzyme.Active reagent layer 820 may further include a citrate buffer atpH 6, a polyvinyl alcohol, a polyvinyl pyrrolidone-vinyl acetate, a Dow Corning DC1500 antifoam, a hydroxyethyl cellulose (Natrosol 250G, Hercules), and a surface modified silica (Cab-o-sil TS 610, Cabot) having both hydrophilic and hydrophobic domains. Examples of oxidized mediators may be ferricyanide, ferricinium complexes, quinone complexes, and osmium complexes. Examples of the enzyme may be glucose oxidase, glucose dehydrogenase using a PQQ co-factor, and glucose dehydrogenase using a nicotinamide adenine dinucleotide co-factor. Becauseactive reagent layer 820 does include the enzyme, the oxidation current measured at first workingelectrode 808 is proportional to the glucose concentration. - It should be noted that if screen printing were used for depositing both
inactive reagent layer 818 andactive reagent layer 820, then two separate screen printing steps would be required to deposit the respective reagent layers onto the appropriate electrode(s). It should be noted that screen printing is not well-suited for printing two discrete reagents on the same screen. The squeegee motion during printing may cause the two respective reagents to mix during the screen printing process.FIG. 3 shows an embodiment of this invention which hasinactive reagent layer 818 disposed on second workingelectrode 806, andactive reagent layer 820 disposed on first workingelectrode 808 andreference electrode 810. In this embodiment,inactive reagent layer 818 does not touch or overlap withactive reagent layer 820. Because the area of second workingelectrode 806, first workingelectrode 808 andreference electrode 810 is relatively small, it can be difficult to sequentially align and coatinactive reagent layer 818 andactive reagent layer 820, respectively, with the desired yield. It should also be noted that relatively small electrode areas (e.g. about 0.6 mm2) are preferred because this allows the volume of liquid sample required for a test strip to be small. - In an embodiment of this invention,
inactive reagent layer 818 is printed first and then dried at an elevated temperature.Active reagent layer 820 is then subsequently printed followed by another drying step at an elevated temperature as described in International Application serial number PCT/GB/03004708 which is hereby incorporated by reference herein. Becauseactive reagent layer 820 is deposited second, it is exposed to only one drying step as opposed to the two drying steps forinactive reagent layer 818. This helps stabilize both mediator and enzyme withinactive reagent layer 820 because under certain conditions enzymes can degrade with continued exposure to elevated temperatures. - In an embodiment of this invention,
FIG. 4 showsinactive reagent layer 818 disposed on second workingelectrode 806, andactive reagent layer 820 disposed on first workingelectrode 808 andreference electrode 810. In this embodimentinactive reagent layer 818 andactive reagent layer 820 are immediately adjacent to each other. In such a case, theinactive reagent layer 818 andactive reagent layer 820 would touch, but typically not overlap with each other to any significant extent. Although the printing process targets the alignment such thatinactive reagent layer 818 andactive reagent layer 820 are immediately adjacent to each other, normal manufacturing variation will cause some overlap to occur with a certain frequency betweeninactive reagent layer 818 andactive reagent layer 820. Likewise, such variation will also causeinactive reagent layer 818 to sometimes not touchactive reagent layer 820. Becauseinactive reagent layer 818 was allowed to touch or not touchactive reagent layer 820 and the operation of the method of the invention still works to reduce the variation in the background in either circumstance, the yield of acceptable test strips was improved. - It should be noted that the overlap of
inactive reagent layer 818 withactive reagent layer 820 does not affect the glucose measurement as long as the enzyme fromactive reagent layer 820 cannot diffuse, to any significant extent in the time allowed for the measurement (i.e. about 5 seconds or less), to second workingelectrode 806. If enzyme were to diffuse to second workingelectrode 806, then first workingelectrode 808 would measure a glucose current in addition to the non-enzyme specific currents. This would preventtest strip 800 from effectively reducing the background signal. - It should also be noted that if the overlap of
inactive reagent layer 818 withactive reagent layer 820 were to occur onreference electrode 810 that this would not affect the glucose measurement. In such a case, the amount of enzyme and/or oxidized mediator onreference electrode 810 will increase, but should not affect the glucose measurement or the background correction algorithm. - Yet another embodiment of this invention which improves upon the method of coating
inactive reagent layer 818 andactive reagent layer 820 is shown inFIG. 5 Inactive reagent layer 818 may be coated such that it completely covers second workingelectrode 806 and a portion ofreference electrode 810. Similarly,active reagent layer 820 may be coated such that it completely covers first workingelectrode 808 and at least a portion ofreference electrode 810. In an embodiment of this invention, the printing process can target the alignment such thatinactive reagent layer 818 andactive reagent layer 820 substantially overlap with each other onreference electrode 810 at anoverlap zone 822. In such a case,inactive reagent layer 818 andactive reagent layer 820 may mix with each other atoverlap zone 822. Because the length of bothinactive reagent layer 818 andactive reagent layer 820 was further increased compared to the embodiment described inFIG. 4 , the alignment and coating ofactive reagent layer 820 andinactive reagent layer 818 to first workingelectrode 808 and second workingelectrode 806 was yet further improved. - It should be noted that second working electrode 806 (e.g. dummy electrode) is located on
distal portion 58 oftest strip 800 as illustrated in FIGS. 1 to 5. This causes the physiological fluid to sequentially wet in the following order—second workingelectrode 806,reference electrode 810, and then first workingelectrode 808.Test strip 800 was purposefully designed to have inactive reagent layer 818 (which contains no enzyme) upstream of active reagent layer 820 (which does contain enzyme). This reduces the possibility of enzyme being present at both second workingelectrode 806 and first workingelectrode 808. Ifactive reagent layer 820, which contains enzyme, was coated over second workingelectrode 806, and no enzyme were present over first workingelectrode 808 then it would be possible that some enzyme could be swept to first workingelectrode 808 from second workingelectrode 806. The presence of a significant amount of enzyme on first workingelectrode 808 would prevent the background signal from being reduced through the use of the dummy electrode format. - In an embodiment of this invention,
top layer 824 may be in the form of anintegrated lance 826 as shown inFIG. 1 . In such an embodiment,top layer 824 may include alance 826 which is located atdistal portion 58.Lance 826, which may also be referred to as a penetration member, may be adapted to pierce a user's skin and draw blood intotest strip 800 such that second workingelectrode 806, first workingelectrode 808, andreference electrode 810 are wetted.Top layer 824 is adhered totest strip 800 byadhesive layer 830. Thisadhesive layer 830 can be a heat seal or a pressure sensitive adhesive.Lance 826 includes alancet base 832 that terminates atdistal portion 58 of assembledtest strip 800.Lance 826 may be made with either an insulating material such as plastic, glass, and silicon, or a conducting material such as stainless steel and gold. For the case in whichtop layer 824 is conductive,top layer 824 may also be used as areference electrode 810 which is orientated with a facing relationship to second workingelectrode 806 and first workingelectrode 808. Further descriptions of integrated medical devices that use an integrated lance can be found in International Application No. PCT/GB01/05634 and U.S. patent application Ser. No. 10/143,399 which are hereby fully incorporated by reference herein. In addition,lance 826 can be fabricated, for example, by a progressive die-stamping technique, as disclosed in the aforementioned International Application No. PCT/GB01/05634 and U.S. patent application Ser. No. 10/143,399 which are hereby fully incorporated by reference herein. - In an embodiment of the present invention,
adhesive layer 830 has a height of about 70 to 110 microns.Adhesive layer 830 may include a double sided pressure sensitive adhesive, a UV cured adhesive, heat activated adhesive, thermosetting plastic, or other adhesive known to those skilled in the art. As a non-limiting example,adhesive layer 830 may be formed by screen printing a pressure sensitive adhesive such as, for example, a water based acrylic copolymer pressure sensitive adhesive which is commercially available from Tape Specialties LTD in Tring, Herts, United Kingdom (part#A6435). - In a method of this invention, the background variations are reduced by subtracting a first current from first working
electrode 808 from a second current from second workingelectrode 806. To initiate a test, a sample is applied to sampleinlet 52 which allows a current to be measured at second workingelectrode 806 and first workingelectrode 808. Because second workingelectrode 806 does not have a glucose oxidizing enzyme disposed thereon, a magnitude of an oxidation current at second workingelectrode 806 is proportional to an amount of interfering compounds present ontest strip 800 and also an amount of interfering compounds originating from the sample. This allows a corrected current value to be calculated using a difference between first workingelectrode 808 and second workingelectrode 806 to reduce the effects of interfering compounds present in the sample and also for interfering compounds that may be present ontest strip 800. -
FIG. 9 is a simplified schematic showing ameter 900 interfacing withtest strip 800.Meter 900 has at least three electrical contacts that form an electrical connection to second workingelectrode 806, first workingelectrode 808, andreference electrode 810. In particularsecond contact 812 andreference contact 816 connect tofirst voltage source 910;first contact 814 andreference contact 816 connect tosecond voltage source 920. When performing a test,first voltage source 910 applies a first potential E1 between second workingelectrode 806 andreference electrode 810; andsecond voltage source 920 applies a second potential E2 between first workingelectrode 808 andreference electrode 810. - In one embodiment of this invention, first potential E1 and second potential E2 may be the same such as for example about +0.4 V. In another embodiment of this invention, first potential E1 and second potential E2 may be different. A sample of blood is applied such that second working
electrode 806, first workingelectrode 808, andreference electrode 810 are covered with blood. This allows second workingelectrode 806 and first workingelectrode 808 to measure a current which is proportional to glucose and/or non-enzyme specific sources. After about 5 seconds from the sample application,meter 900 measures an oxidation current for both second workingelectrode 806 and first workingelectrode 808. -
FIG. 10 is a simplified schematic showing ameter 900 interfacing withtest strip 800. In contrast toFIG. 9 ,top layer 824 is conductive and used as a reference electrode instead ofreference electrode 810 which is disposed onsubstrate 50. More particularly,FIG. 10 shows thattop layer 824, in the form of a reference electrode, has a facing relationship with first workingelectrode 808 and second workingelectrode 806. In this case,meter 900 forms an electrical contact totop layer 824 instead of atreference contact 816 as is shown inFIG. 1 . -
FIG. 21 is an exploded perspective view of atest strip 1000 according to another embodiment of the present invention. The oxidation current measured at a first workingelectrode 100 will be a superposition of oxidation current sources: a first, desirable, oxidation current generated by the oxidation of glucose and a second, undesirable, oxidation current generated by the interferents. The oxidation of interferents may occur directly at first workingelectrode 100 and indirectly through a mediated mechanism via a mediator. - Second working
electrode 102 has a geometric trace that has anactive portion 102 a which is coated withactive reagent 820 and aninactive portion 102 i which is coated withinactive reagent 818 as illustrated in FIGS. 22 to 27. The oxidation current sources measured atactive portion 102 a will be similar to first workingelectrode 100.Inactive portion 102 i of second workingelectrode 102 will oxidize interferents and not oxidize glucose because there is no enzyme present. Further,inactive portion 102 i will oxidize interferents directly at second workingelectrode 102 and indirectly through a mediated mechanism via a mediator. Because the oxidation current measured atinactive portion 102 i does not depend on glucose and the area ofinactive portion 102 i is known, it is possible to calculate its contribution to the interferent oxidation current measured at second workingelectrode 102. In turn, using the interferent oxidation current calculated forinactive portion 102 i and knowing the area of first workingelectrode 100 and the area ofactive portion 102 a, it is possible to calculate a corrected glucose current which accounts for the effects of interfering compounds oxidized at the electrode. It should be noted that in the present invention,inactive portion 102 i helps correct the glucose current for direct and mediated interference oxidation. It should also be noted thatinactive portion 102 i andactive portion 102 a may sometimes by referred to as an inactive region and an active region, respectively. - An algorithm may, therefore be used to calculate a corrected glucose current that is independent of interferences. After dosing a sample onto
test strip 1000, a constant potential is applied to first workingelectrode 100 and second workingelectrode 102 and a current is measured for both electrodes. At first workingelectrode 100 whereactive reagent layer 820 covers the entire electrode area, the following equation can be used to describe the components contributing to the oxidation current,
WE 1 =G+I 1a (Eq 1)
where WE1 is a current density at the first working electrode, G is a current density due to glucose which is independent of interferences, and I1a is a current density due to interferences oxidized at first workingelectrode 100 which is covered withactive reagent 820. - At second working
electrode 102 which is partially covered withactive reagent 820 andinactive reagent 818, the following equation can be used to describe the components contributing to the oxidation current,
WE 2 =G+I 2a +I 2i (Eq 2)
where WE2 is a current density at the second working electrode, I2a is a current density due to interferences at theactive portion 102 a, and 12 i is a current density due to interferences atinactive portion 102 i. - To reduce the effects of interferences, an equation is formulated which describes the relationship between the interferent current at
active portion 102 a andinactive portion 102 i. It is approximated that the interferent oxidation current density measured atactive portion 102 a is the same as the current density measured at theinactive portion 102 i. This relationship is further described by the following equation,
where A2a is an area of second working electrode covered withactive reagent layer 820 and A2i is an area of second working electrode covered withinactive reagent layer 818. -
Inactive portion 102 i can oxidize interferents, but not glucose because it is not coated with enzyme.Active portion 102 a can oxidize glucose and interferents. Because it was experimentally found thatinactive portion 102 i oxidizes interferents in a manner proportional to the area ofactive portion 102 a, it is possible to predict the proportion of interferent current measured overall at second workingelectrode 102. This allows the overall current measured at second working electrode 102 (i.e. WE2) to be corrected by subtracting the contribution of the interferent current. In an embodiment of the present invention the ratio of A2i:A2a may be between about 0.5:1 to 5:1, and is preferably about 3:1. More details describing this mathematical algorithm for current correction will be described in the subsequent sections. - In an alternative embodiment of the present invention, I2a may be different than I2i. This may be ascribed to a more efficient or less efficient oxidation of interferents at the
active portion 102 a because of the presence of enzyme. For not well described reasons, it is possible that the presence of enzyme may affect the electrode's ability to oxidize mediator and/or interferents. This behavior may be phenomenologically modeled by re-writing Equation 3a to the following form,
I 2a =f×I 2i (Eq 3b)
where f is a correction factor which incorporates the effects of the interferent oxidation efficiency of theactive portion 102 a to inactive portion 120 i. - In an embodiment of the present invention,
Equation Equation active reagent layer 820.Equation 1 can be rearranged to the following form.
G=WE 1 −I 1a =WE 1 −I 2a (Eq 4)
Next, I2a from Equation 3a can be substituted intoEquation 4 to yieldEquation 5.
Next,Equation 1 andEquation 2 can be combined to yieldEquation 6.
I 2i =WE 2 −WE 1 (Eq 6)
Next, I2i fromEquation 6 can be substituted intoEquation 5 to yield Equation 7a. - Equation 7a outputs a corrected glucose current density G which removes the effects of interferences requiring only the measured current density from first working
electrode 100 and second working electrode 102 (i.e. WE1 and WE2), and a proportion of an area of the second working electrode covered with active reagent to an area of the second working electrode covered withinactive reagent
). In one embodiment of the present invention theproportion
may be programmed into a glucose meter, in, for example, a read only memory. In another embodiment of the present invention, theproportion
may be transferred to the meter via a calibration code chip which would may account for manufacturing variations in A2a or A2i. - In an alternative embodiment to the
present invention Equation active portion 102 a is different from the interferent oxidation current density ofinactive portion 102 i. In such a case, an alternative correction Equation 7b is derived as shown below.
G=WE 1 −{f×(WE 2 −WE 1)} (Eq 7b) - In another embodiment of the present invention, the corrected glucose current Equation 7a or 7b may be used by the meter only when a certain threshold is exceeded. For example, if WE2 is about 10% or greater than WE1, then the meter would use Equation 7a or 7b to correct for the current output. However, if WE2 is about 10% or less than WE1, the meter would simple take an average current value between WE1 and WE2 to improve the accuracy and precision of the measurement. The strategy of using Equation 7a or 7b only under certain situations where it is likely that a significant level of interferences are in the sample mitigates the risk of overcorrecting the measured glucose current. It should be noted that when WE2 is sufficiently greater than WE1 (e.g. about 20% or more), this is an indicator of having a sufficiently high concentration of interferents. In such a case, it may be desirable to output an error message instead of a glucose value because a very high level of interferents may cause a breakdown in the accuracy of Equation 7a or 7b.
-
FIG. 21 shows an exploded perspective view of a test strip embodiment that is designed to compensate for variations in increased background caused by the conversion of oxidized mediator to reduced mediator.Test strip 1000 includes asubstrate 50, aconductive layer 164, aninsulation layer 106, aninactive reagent layer 818, anactive reagent layer 820, anadhesive layer 830, and atop layer 824.Test strip 1000 further includes adistal end 58 and aproximal end 60. It should be noted thattest strip 1000 is a modification oftest strip 800 so that anactive reagent coating 820 covers a portion of both a first workingelectrode 100 and asecond working electrode 102. This allows for two glucose measurements to be made while at the same time allows for the correction of interferents which develop withintest strip 1000 or are dosed intotest strip 1000.Test strip 1000 would employ either Equation 7a or 7b for reducing the effect of interfering compounds or increased background. In contrast totest strip 800,test strip 1000 has a modification toconductive layer 164 andinsulation layer 106.Substrate 50,inactive reagent layer 818,active reagent layer 820,adhesive layer 830 andtop layer 824 are similar in both shape and material for bothtest strip 1000 andtest strip 800. - FIGS. 22 to 24 are a simplified plane view of
distal portion 58 oftest strip 1000, according to the embodiment of the present invention illustrated inFIG. 21 , which show various positions ofactive reagent layer 820 andinactive reagent layer 818 with respect to each other. FIGS. 25 to 27, which correspond to FIGS. 22 to 24 respectively, do not showinsulation layer 804 to help demonstrate more clearly the relationship between theconductive layer 164,active reagent layer 820, andinactive reagent layer 818. - In
test strip 1000,conductive layer 164 is disposed onsubstrate 50.Conductive layer 164 includes a first workingelectrode 100, asecond working electrode 102, areference electrode 104, afirst contact 101, asecond contact 103, areference contact 105, astrip detection bar 17, as shown inFIG. 21 . In contrast totest strip 800, second workingelectrode 806 and first workingelectrode 102 has a C-shape. -
FIG. 22 is a simplified plane view of first workingelectrode 100, second workingelectrode 102, andreference electrode 104,insulation layer 106,inactive reagent layer 818, andactive reagent layer 820.Insulation layer 106 includes acutout 108 which defines the area of second workingelectrode 102 to have aninactive portion 102 i and anactive portion 102 a. In this embodiment,inactive reagent layer 818 was disposed oninactive portion 102 i andactive reagent layer 820 was disposed onactive portion 102 a, first workingelectrode 100, andreference electrode 104.FIG. 22 shows thatinactive reagent layer 818 does not touch or overlap withactive reagent layer 820. -
Test strip 1000 differs fromtest strip 800 in that bothinactive reagent layer 818 andactive reagent layer 820 both coat a portion of second workingelectrode 102. This allows two glucose measurements to be performed while at the same time reduce the effects of background and/or interferences. One of the challenges with makingtest strip 1000 as shown inFIG. 22 is that it can be difficult to sequentially align and coat the respectiveinactive reagent layer 818 andactive reagent layer 820 so that they do not touch each other with the desired yield because the area of first workingelectrode 100, second workingelectrode 102 andreference electrode 104 is relatively small. - In an embodiment of this invention,
FIG. 23 showsinactive reagent layer 818 disposed oninactive portion 102 i, andactive reagent layer 820 disposed onactive portion 102 a, first workingelectrode 100, andreference electrode 104. In this embodimentinactive reagent layer 818 andactive reagent layer 820 are immediately adjacent to each other. In such an ideal case theinactive reagent layer 818 andactive reagent layer 820 would touch, but not substantially overlap with each other. Although the printing process targets the alignment such thatinactive reagent layer 818 andactive reagent layer 820 are immediately adjacent to each other, normal manufacturing variation will cause some overlap to occur with a certain frequency betweeninactive reagent layer 818 andactive reagent layer 820. Likewise, such variation will also causeinactive reagent layer 818 to not touchactive reagent layer 820 at a certain frequency. Becauseinactive reagent layer 818 was allowed to touch or not touchactive reagent layer 820, the yield of acceptable test strips was improved. - Yet another embodiment of this invention which improves upon the method of coating
inactive reagent layer 818 andactive reagent layer 820 is shown inFIG. 24 .Inactive reagent layer 818 may be coated such that it completely coversinactive portion 102 i and a portion ofreference electrode 104. Similarly,active reagent layer 820 may be coated such that it completely coversactive portion 102 a, first workingelectrode 100 and at least a portion ofreference electrode 104. In an embodiment of this invention, the printing process can target the alignment such thatinactive reagent layer 818 andactive reagent layer 820 substantially overlap with each other onreference electrode 810 at anoverlap zone 822. In such a case,inactive reagent layer 818 andactive reagent layer 820 may mix with each other atoverlap zone 822. Because the length of bothinactive reagent layer 818 andactive reagent layer 820 was further increased compared to the embodiment described inFIG. 23 , the alignment and coating ofactive reagent layer 820 andinactive reagent layer 818 was yet further improved in terms of manufacturing yield. - It is an advantage of this invention in that two reagent layers are used which helps reduce the effects of increased background. The ability to sufficiently compensate for varying levels of reduced mediator such as ferrocyanide in the test strip itself enables a high level of accuracy and precision to be achieved. There are several factors that may influence the conversion of oxidized mediator to the reduced form during the manufacturing, testing, and storage process. Therefore, this allows for corrections to be made which account for manufacturing variations such as reagent layer height (within batch and batch-to-batch), heat seal adhesive manufacturing conditions, high temperature drying, packaging, and sterilization conditions. Because the correction accounts for these variation, a more robust process can be envisaged in which rigorous process controls are not needed to monitor and control such manufacturing variations. The measurement of background currents may also improve the stability of test strip to withstand adverse storage conditions such as high temperature and humidity. This may allow simpler cartridges to be designed for storing test strips which may not need a rigorous seal to withhold moisture.
-
Test strips 800 were prepared as illustrated in FIGS. 1 to 3 a.Test strips 800 were tested in blood which were exposed to varying levels of sterilizing radiation. Totest strips 800, they were electrically connected to a potentiostat which has the means to apply a constant potential of +0.4 volts between first workingelectrode 808 andreference electrode 810; and second workingelectrode 806 and thereference electrode 810. A sample of blood is applied to sampleinlet 52 allowing the blood to wick into the sample receiving chamber and to wet first workingelectrode 808,reference electrode 810, and second workingelectrode 806.Active layer 820 becomes hydrated with blood and then generates ferrocyanide which may be proportional to the amount of glucose and/or interferent concentration present in the sample. In contrast,inactive layer 818 becomes hydrated with blood and does not generate additional ferrocyanide that was not present withininactive layer 818 before hydration. After about 5 seconds from the sample application totest strip 800, an oxidation of ferrocyanide and/or interferences are measured as a current for both first workingelectrode 808 and second workingelectrode 806. - Two batches of test strips were prepared to show that the use of
inactive reagent layer 818 andactive reagent layer 820 improved the overall precision for test strips sterilized by gamma radiation. Both batches of test strips were tested in a similar manner as described in Example 1. The first test strip batch istest strip 800 and is referred to asBatch 1. The second test strip batch, which is referred to asBatch 2, is also similar totest strip 800, but does not includeinactive reagent layer 818 and also has a modified active reagent layer which covers both first workingelectrode 808, second workingelectrode 806, andreference electrode 810. When testingBatch 1, the difference in current from first workingelectrode 808 and second workingelectrode 806 was used to calculate a corrected signal current which was then converted to a glucose concentration. When testingBatch 2, the current from second workingelectrode 806 and first workingelectrode 808 were summed together to determine a value which was then used to calculate an uncorrected glucose concentration. Before testing with blood, bothBatch 1 andBatch 2 test strips were treated with 0 kGy and 25 kGy of gamma radiation. Next, the four test cases, which areBatch 1—0 kGy,Batch 1—25 kGy,Batch 2—0 kGy, andBatch 2—25 kGy, were evaluated for precision by testing 24 test strips with blood for each test case at 5 glucose concentrations which was 20, 50, 100, 300, and 500 mg/dL. - FIGS. 11 to 15 show that
Batch 1 test strips did not suffer from a degradation in precision after being sterilized with 25 kGy of gamma radiation. For all five glucose concentrations, the precision was substantially similar or better after sterilization forBatch 1 test strips. This shows that the use ofactive reagent layer 820 andinactive reagent layer 818 helps compensate for background levels of ferrocyanide produced during the sterilization process. - FIGS. 11 to 13 show that
Batch 2 test strips did suffer from a degradation in precision after being sterilized with 25 kGy of gamma radiation. This control experiment verifies that there is a degradation in precision when not using the background reduction method of the present invention. BecauseBatch 2 test strip did not haveinactive reagent layer 818, the background reduction method could not be implemented.Batch 2 test strips, did not suffer from a degradation in precision after being sterilized because relatively high glucose concentrations were tested (300 and 500 mg/dL) in which the effect of sterilization on precision is not as significant. In this case, the amount of ferrocyanide generated by glucose oxidase is significantly higher than ferrocyanide generated (e.g. by sterilization processes) before hydrating the test strip. - Another batch of test strips, which is referred to as
Batch 3, was prepared in a manner similar totest strip 800 except that second workingelectrode 806 was not coated with eitheractive reagent layer 820 orinactive reagent layer 818. In this example,Batches 1 to 3 were tested to evaluate the overall accuracy in the presence of interfering compounds such as uric acid and gentisic acid. -
Batch 1,Batch 2, andBatch 3 test strips were tested in blood at three concentrations of gentisic acid which were 0, 25, and 50 mg/dL. For each gentisic acid concentration, two glucose concentrations were tested which were 70 and 240 mg/dL.FIGS. 16 and 17 show thatBatch 1 andBatch 3 test strips had an insignificant change (<10 mg/dL or 10%) in bias when testing them at 25 and 50 mg/dL gentisic acid concentration. In contrast,Batch 2 test strips had a significant change (>10 mg/dL or 10%) in bias when testing them at a 25 and a 50 mg/dL gentisic acid concentration. This shows that the use of second workingelectrode 806 not coated with enzyme allows for an effective correction of the glucose signal in the presence of high concentrations of gentisic acid. -
Batch 1,Batch 2, andBatch 3 test strips were tested in blood at three concentrations of uric acid which were 0, 10, and 20 mg/dL. For each uric acid concentration, two glucose concentrations were tested which were 70 and 240 mg/dL.FIGS. 18 and 19 show thatBatch 1 andBatch 3 test strips had an insignificant change (<10 mg/dL or 10%) in bias when testing them at 10 and 20 mg/dL uric acid concentration. In contrast,Batch 2 test strips had a significant change (>10 mg/dL or 10%) in bias when testing them at a 10 and a 20 mg/dL uric acid concentration. This shows that the use of second workingelectrode 806 not coated with enzyme allows for an effective correction of the glucose signal in the presence of high concentrations of uric acid. - It will be recognized that equivalent structures may be substituted for the structures illustrated and described herein and that the described embodiment of the invention is not the only structure which may be employed to implement the claimed invention. In addition, it should be understood that every structure described above has a function and such structure can be referred to as a means for performing that function. While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to hose skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims (2)
1. A method of reducing interferences in an electrochemical sensor comprising:
measuring a first current at a first working electrode, said first working electrode being covered by an active reagent layer;
measuring a second current at a second working electrode, said second working electrode being covered by an inactive reagent layer; and
calculating a corrected current value representative of a glucose concentration which subtracts said second current from said first current.
2. A method of reducing interferences in an electrochemical sensor comprising:
measuring a first current at a first working electrode, said first working electrode being covered by an active reagent layer;
measuring a second current at a second working electrode, wherein said active reagent layer is disposed on an active region of said second working electrode and an inactive region of said second working electrode is covered by an inactive reagent layer; and
calculating a corrected current value representative of a glucose concentration using a ratio of an active region on said first and second working electrodes and an inactive region on said second working electrode.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/977,086 US20050139489A1 (en) | 2003-10-31 | 2004-10-29 | Method of reducing the effect of direct and mediated interference current in an electrochemical test strip |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51625203P | 2003-10-31 | 2003-10-31 | |
US55842404P | 2004-03-31 | 2004-03-31 | |
US55872804P | 2004-03-31 | 2004-03-31 | |
US10/977,086 US20050139489A1 (en) | 2003-10-31 | 2004-10-29 | Method of reducing the effect of direct and mediated interference current in an electrochemical test strip |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050139489A1 true US20050139489A1 (en) | 2005-06-30 |
Family
ID=34577659
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/976,489 Abandoned US20050133368A1 (en) | 2003-10-31 | 2004-10-29 | Electrochemical test strip for reducing the effect of direct interference current |
US10/977,292 Abandoned US20050114062A1 (en) | 2003-10-31 | 2004-10-29 | Method of reducing the effect of direct interference current in an electrochemical test strip |
US10/977,154 Expired - Fee Related US7618522B2 (en) | 2003-10-31 | 2004-10-29 | Method of reducing interferences in an electrochemical sensor using two different applied potentials |
US10/977,086 Abandoned US20050139489A1 (en) | 2003-10-31 | 2004-10-29 | Method of reducing the effect of direct and mediated interference current in an electrochemical test strip |
US10/977,316 Abandoned US20050139469A1 (en) | 2003-10-31 | 2004-10-29 | Electrochemical test strip for reducing the effect of direct and mediated interference current |
US10/577,586 Expired - Lifetime US7653492B2 (en) | 2003-10-31 | 2004-10-29 | Method of reducing the effect of direct interference current in an electrochemical test strip |
US12/574,469 Abandoned US20100018878A1 (en) | 2003-10-31 | 2009-10-06 | Method of reducing interferences in an electrochemical sensor using two different applied potentials |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/976,489 Abandoned US20050133368A1 (en) | 2003-10-31 | 2004-10-29 | Electrochemical test strip for reducing the effect of direct interference current |
US10/977,292 Abandoned US20050114062A1 (en) | 2003-10-31 | 2004-10-29 | Method of reducing the effect of direct interference current in an electrochemical test strip |
US10/977,154 Expired - Fee Related US7618522B2 (en) | 2003-10-31 | 2004-10-29 | Method of reducing interferences in an electrochemical sensor using two different applied potentials |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/977,316 Abandoned US20050139469A1 (en) | 2003-10-31 | 2004-10-29 | Electrochemical test strip for reducing the effect of direct and mediated interference current |
US10/577,586 Expired - Lifetime US7653492B2 (en) | 2003-10-31 | 2004-10-29 | Method of reducing the effect of direct interference current in an electrochemical test strip |
US12/574,469 Abandoned US20100018878A1 (en) | 2003-10-31 | 2009-10-06 | Method of reducing interferences in an electrochemical sensor using two different applied potentials |
Country Status (15)
Country | Link |
---|---|
US (7) | US20050133368A1 (en) |
EP (6) | EP1678490B1 (en) |
JP (6) | JP2007514928A (en) |
KR (5) | KR20070027496A (en) |
AT (4) | ATE460661T1 (en) |
AU (6) | AU2004288011A1 (en) |
CA (6) | CA2543797C (en) |
DE (4) | DE602004006148T2 (en) |
DK (3) | DK1685393T3 (en) |
ES (4) | ES2327741T3 (en) |
IL (6) | IL175323A0 (en) |
PL (3) | PL1678489T3 (en) |
PT (2) | PT1678489E (en) |
SG (2) | SG131942A1 (en) |
WO (6) | WO2005045417A1 (en) |
Cited By (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137998A1 (en) * | 2001-03-26 | 2002-09-26 | Wilson Smart | Silicon microprobe with integrated biosensor |
US20030018282A1 (en) * | 2001-07-20 | 2003-01-23 | Carlo Effenhauser | System for withdrawing small amounts of body fluid |
US20050043598A1 (en) * | 2003-08-22 | 2005-02-24 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US20050109618A1 (en) * | 2003-10-31 | 2005-05-26 | Davies Oliver W.H. | Meter for use in an improved method of reducing interferences in an electrochemical sensor using two different applied potentials |
US20050183965A1 (en) * | 2003-10-31 | 2005-08-25 | Davies Oliver William H. | Method of reducing interferences in an electrochemical sensor using two different applied potentials |
US20060189856A1 (en) * | 2003-07-25 | 2006-08-24 | James Petisce | Oxygen enhancing membrane systems for implantable devices |
US20060200045A1 (en) * | 2005-03-02 | 2006-09-07 | Roe Steven N | Dynamic integrated lancing test strip with sterility cover |
US20070167869A1 (en) * | 2005-03-02 | 2007-07-19 | Roe Steven N | System and method for breaking a sterility seal to engage a lancet |
WO2008050145A1 (en) * | 2006-10-27 | 2008-05-02 | Suresensors Ltd | Measurement device |
US20080199937A1 (en) * | 2005-03-04 | 2008-08-21 | Chu Amy H | Reagent Composition and Methods of Using and Forming the Same |
WO2008042918A3 (en) * | 2006-10-04 | 2008-09-04 | Dexcom Inc | Dual electrode system for a continuous analyte sensor |
US20080242961A1 (en) * | 2004-07-13 | 2008-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20090010802A1 (en) * | 2002-12-27 | 2009-01-08 | Abner David Joseph | Method for manufacturing a sterilized lancet integrated biosensor |
US20090062633A1 (en) * | 2004-05-03 | 2009-03-05 | Dexcorn, Inc. | Implantable analyte sensor |
US20090192366A1 (en) * | 2007-12-17 | 2009-07-30 | Dexcom, Inc | Systems and methods for processing sensor data |
USD598126S1 (en) * | 2008-06-06 | 2009-08-11 | Lifescan Scotland Limited | Electrochemical test strip |
US20090247856A1 (en) * | 2008-03-28 | 2009-10-01 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US7715893B2 (en) | 2003-12-05 | 2010-05-11 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US20100161269A1 (en) * | 2003-08-01 | 2010-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7771352B2 (en) | 1997-03-04 | 2010-08-10 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US7792562B2 (en) | 1997-03-04 | 2010-09-07 | Dexcom, Inc. | Device and method for determining analyte levels |
US20100228109A1 (en) * | 2004-07-13 | 2010-09-09 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20100280341A1 (en) * | 2008-03-28 | 2010-11-04 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US7828728B2 (en) | 2003-07-25 | 2010-11-09 | Dexcom, Inc. | Analyte sensor |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7857760B2 (en) | 2004-07-13 | 2010-12-28 | Dexcom, Inc. | Analyte sensor |
US7860544B2 (en) | 1998-04-30 | 2010-12-28 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US20100331657A1 (en) * | 2008-02-21 | 2010-12-30 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US20100327886A1 (en) * | 2008-03-27 | 2010-12-30 | Toshifumi Nakamura | Measurement device, measurement system, and concentration measurement method |
US7881763B2 (en) | 2003-04-04 | 2011-02-01 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US20110048972A1 (en) * | 2009-08-31 | 2011-03-03 | Lifescan Scotland Limited | Multi-analyte test strip with shared counter/reference electrode and inline electrode configuration |
US7905833B2 (en) | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7914450B2 (en) | 2003-08-01 | 2011-03-29 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
US7927274B2 (en) | 2003-11-19 | 2011-04-19 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US7976492B2 (en) | 2004-02-26 | 2011-07-12 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8000901B2 (en) | 2003-08-01 | 2011-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8005524B2 (en) | 2003-12-09 | 2011-08-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8064977B2 (en) | 2002-05-22 | 2011-11-22 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
US8155723B2 (en) | 1997-03-04 | 2012-04-10 | Dexcom, Inc. | Device and method for determining analyte levels |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8233959B2 (en) | 2003-08-22 | 2012-07-31 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US8280475B2 (en) | 2004-07-13 | 2012-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8287454B2 (en) | 1998-04-30 | 2012-10-16 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8509871B2 (en) | 2001-07-27 | 2013-08-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US8548553B2 (en) | 2003-08-01 | 2013-10-01 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US8562558B2 (en) | 2007-06-08 | 2013-10-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8612159B2 (en) | 1998-04-30 | 2013-12-17 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8622905B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8652043B2 (en) | 2001-01-02 | 2014-02-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8679310B2 (en) * | 2010-04-22 | 2014-03-25 | Arkray, Inc. | Biosensor |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
USD701864S1 (en) * | 2012-04-23 | 2014-04-01 | Blackberry Limited | UICC apparatus |
USD702240S1 (en) * | 2012-04-13 | 2014-04-08 | Blackberry Limited | UICC apparatus |
US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US8777853B2 (en) | 2003-08-22 | 2014-07-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US8936199B2 (en) | 2012-04-13 | 2015-01-20 | Blackberry Limited | UICC apparatus and related methods |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9446194B2 (en) | 2009-03-27 | 2016-09-20 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US9451908B2 (en) | 2006-10-04 | 2016-09-27 | Dexcom, Inc. | Analyte sensor |
US9451910B2 (en) | 2007-09-13 | 2016-09-27 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9986942B2 (en) | 2004-07-13 | 2018-06-05 | Dexcom, Inc. | Analyte sensor |
US10653835B2 (en) | 2007-10-09 | 2020-05-19 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US10966609B2 (en) | 2004-02-26 | 2021-04-06 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US10980461B2 (en) | 2008-11-07 | 2021-04-20 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11382539B2 (en) | 2006-10-04 | 2022-07-12 | Dexcom, Inc. | Analyte sensor |
US11559260B2 (en) | 2003-08-22 | 2023-01-24 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
Families Citing this family (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998035225A1 (en) | 1997-02-06 | 1998-08-13 | E. Heller & Company | Small volume in vitro analyte sensor |
US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
DE10057832C1 (en) | 2000-11-21 | 2002-02-21 | Hartmann Paul Ag | Blood analysis device has syringe mounted in casing, annular mounting carrying needles mounted behind test strip and being swiveled so that needle can be pushed through strip and aperture in casing to take blood sample |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
WO2002100460A2 (en) | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Electric lancet actuator |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
DE60239132D1 (en) | 2001-06-12 | 2011-03-24 | Pelikan Technologies Inc | APPARATUS FOR INCREASING THE SUCCESS RATE IN RESPECT OF BLOOD EXPLOITATION OBTAINED BY A FINGERSTICK |
US7749174B2 (en) | 2001-06-12 | 2010-07-06 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
ES2336081T3 (en) | 2001-06-12 | 2010-04-08 | Pelikan Technologies Inc. | SELF-OPTIMIZATION PUNCTURE DEVICE WITH MEANS OF ADAPTATION TO TEMPORARY VARIATIONS IN CUTANEOUS PROPERTIES. |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
EP1404232B1 (en) | 2001-06-12 | 2009-12-02 | Pelikan Technologies Inc. | Blood sampling apparatus and method |
US7041068B2 (en) | 2001-06-12 | 2006-05-09 | Pelikan Technologies, Inc. | Sampling module device and method |
AU2002320094A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Integrated blood sampling analysis system with multi-use sampling module |
US7344894B2 (en) | 2001-10-16 | 2008-03-18 | Agilent Technologies, Inc. | Thermal regulation of fluidic samples within a diagnostic cartridge |
US7374544B2 (en) | 2002-04-19 | 2008-05-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
US7481776B2 (en) | 2002-04-19 | 2009-01-27 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US7563232B2 (en) | 2002-04-19 | 2009-07-21 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7524293B2 (en) | 2002-04-19 | 2009-04-28 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7708701B2 (en) | 2002-04-19 | 2010-05-04 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7141058B2 (en) | 2002-04-19 | 2006-11-28 | Pelikan Technologies, Inc. | Method and apparatus for a body fluid sampling device using illumination |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7410468B2 (en) | 2002-04-19 | 2008-08-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7582099B2 (en) | 2002-04-19 | 2009-09-01 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7767068B2 (en) | 2002-12-02 | 2010-08-03 | Epocal Inc. | Heterogeneous membrane electrodes |
US7842234B2 (en) * | 2002-12-02 | 2010-11-30 | Epocal Inc. | Diagnostic devices incorporating fluidics and methods of manufacture |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
EP1628567B1 (en) | 2003-05-30 | 2010-08-04 | Pelikan Technologies Inc. | Method and apparatus for fluid injection |
ES2490740T3 (en) | 2003-06-06 | 2014-09-04 | Sanofi-Aventis Deutschland Gmbh | Apparatus for blood fluid sampling and analyte detection |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US7604592B2 (en) | 2003-06-13 | 2009-10-20 | Pelikan Technologies, Inc. | Method and apparatus for a point of care device |
US7366556B2 (en) * | 2003-12-05 | 2008-04-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7424318B2 (en) * | 2003-12-05 | 2008-09-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7467003B2 (en) * | 2003-12-05 | 2008-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7460898B2 (en) * | 2003-12-05 | 2008-12-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
EP1671096A4 (en) | 2003-09-29 | 2009-09-16 | Pelikan Technologies Inc | METHOD AND APPARATUS FOR AN IMPROVED SAMPLING INTERFERENCE DEVICE |
EP1680014A4 (en) | 2003-10-14 | 2009-01-21 | Pelikan Technologies Inc | METHOD AND DEVICE FOR A VARIABLE USER INTERFACE |
EP2579031B1 (en) * | 2003-12-04 | 2017-09-27 | Panasonic Healthcare Holdings Co., Ltd. | Biosensor for measuring blood component and hematocrit. |
US20100185071A1 (en) * | 2003-12-05 | 2010-07-22 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
WO2005065414A2 (en) | 2003-12-31 | 2005-07-21 | Pelikan Technologies, Inc. | Method and apparatus for improving fluidic flow and sample capture |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
US8828203B2 (en) | 2004-05-20 | 2014-09-09 | Sanofi-Aventis Deutschland Gmbh | Printable hydrogels for biosensors |
WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
EP1835848A4 (en) * | 2004-12-30 | 2009-07-29 | Pelikan Technologies Inc | METHOD AND DEVICE FOR TEST TIME OF ANALYTE MEASUREMENT |
EP1913384B1 (en) | 2005-08-05 | 2009-10-28 | Bayer Healthcare, LLC | Method for distinguishing electrochemical sensors |
WO2007022485A2 (en) * | 2005-08-19 | 2007-02-22 | Becton, Dickinson And Company | Sterilization of biosensors |
EP1921978B1 (en) * | 2005-09-09 | 2012-08-01 | F. Hoffmann-La Roche AG | Device and program for diabetes care |
US20090134043A1 (en) * | 2005-11-10 | 2009-05-28 | Kevin Ward | Non-biofouling, universal redox electrode and measurement system |
EP1969135B1 (en) * | 2005-12-27 | 2017-06-21 | Ascensia Diabetes Care Holdings AG | Process of making electrodes for test sensors |
US8163162B2 (en) * | 2006-03-31 | 2012-04-24 | Lifescan, Inc. | Methods and apparatus for analyzing a sample in the presence of interferents |
US7909983B2 (en) * | 2006-05-04 | 2011-03-22 | Nipro Diagnostics, Inc. | System and methods for automatically recognizing a control solution |
WO2007133457A2 (en) * | 2006-05-08 | 2007-11-22 | Bayer Healthcare Llc | Electrochemical test sensor with reduced sample volume |
DE102006043718B4 (en) * | 2006-09-18 | 2014-12-31 | Alexander Adlassnig | Determination of hydrogen peroxide concentrations |
WO2008040982A1 (en) * | 2006-10-05 | 2008-04-10 | Lifescan Scotland Limited | Method for determining hematocrit corrected analyte concentrations |
US9046480B2 (en) | 2006-10-05 | 2015-06-02 | Lifescan Scotland Limited | Method for determining hematocrit corrected analyte concentrations |
WO2008040998A2 (en) | 2006-10-05 | 2008-04-10 | Lifescan Scotland Limited | Systems and methods for determining a substantially hematocrit independent analyte concentration |
WO2008040990A2 (en) | 2006-10-05 | 2008-04-10 | Lifescan Scotland Limited | Methods for determining an analyte concentration using signal processing algorithms |
TW200823456A (en) * | 2006-11-24 | 2008-06-01 | Health & Life Co Ltd | Biosensor |
KR100909620B1 (en) * | 2007-04-20 | 2009-07-27 | 주식회사 영텍 | Calibration device |
US8236166B2 (en) * | 2007-04-27 | 2012-08-07 | Abbott Diabetes Care Inc. | No calibration analyte sensors and methods |
US8709709B2 (en) | 2007-05-18 | 2014-04-29 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
WO2008144481A1 (en) * | 2007-05-18 | 2008-11-27 | Institute For Molecular Medicine, Inc. | Measurement and uses of oxidative status |
TWI336782B (en) * | 2007-07-05 | 2011-02-01 | Apex Biotechnology Corp | Composite modified electrode trip |
CN101779120B (en) * | 2007-07-26 | 2013-11-27 | 埃葛梅崔克斯股份有限公司 | Electrochemical test strips |
USD612279S1 (en) | 2008-01-18 | 2010-03-23 | Lifescan Scotland Limited | User interface in an analyte meter |
IL197532A0 (en) | 2008-03-21 | 2009-12-24 | Lifescan Scotland Ltd | Analyte testing method and system |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
USD611151S1 (en) | 2008-06-10 | 2010-03-02 | Lifescan Scotland, Ltd. | Test meter |
USD611372S1 (en) | 2008-09-19 | 2010-03-09 | Lifescan Scotland Limited | Analyte test meter |
US8956308B2 (en) | 2008-09-29 | 2015-02-17 | Bayer Healthcare Llc | Integrated-testing system |
US8986208B2 (en) * | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
US8012428B2 (en) * | 2008-10-30 | 2011-09-06 | Lifescan Scotland, Ltd. | Analytical test strip with minimal fill-error sample viewing window |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
KR100918027B1 (en) * | 2009-02-19 | 2009-09-18 | 주식회사 올메디쿠스 | Biosensor with code electrode, manufacturing method thereof, and sensor information acquisition method thereof |
JP5352670B2 (en) * | 2009-08-31 | 2013-11-27 | パナソニック株式会社 | Sensor and concentration measuring method |
KR101109857B1 (en) * | 2009-09-29 | 2012-02-14 | 광운대학교 산학협력단 | Biosensor using double pulse method |
IL209760A (en) * | 2009-12-11 | 2015-05-31 | Lifescan Scotland Ltd | Fill sufficiency method and system |
GB201005359D0 (en) | 2010-03-30 | 2010-05-12 | Menai Medical Technologies Ltd | Sampling plate |
GB201005357D0 (en) | 2010-03-30 | 2010-05-12 | Menai Medical Technologies Ltd | Sampling plate |
US20120238841A1 (en) * | 2010-04-15 | 2012-09-20 | Mark Castle | Sample capture in one step for test strips |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
JP5925285B2 (en) * | 2010-04-22 | 2016-05-25 | アークレイ株式会社 | Biosensor |
GB201007711D0 (en) | 2010-05-07 | 2010-06-23 | Pa Consulting Services | Devices and methods for testing analytes |
US8940141B2 (en) * | 2010-05-19 | 2015-01-27 | Lifescan Scotland Limited | Analytical test strip with an electrode having electrochemically active and inert areas of a predetermined size and distribution |
US20110290668A1 (en) * | 2010-05-27 | 2011-12-01 | Lifescan Scotland Limited | Analytical test strip with crossroads exposed electrode configuration |
WO2012017306A2 (en) | 2010-08-06 | 2012-02-09 | Schlumberger Technology B.V. | Electrochemical sensor |
US20120048746A1 (en) * | 2010-08-30 | 2012-03-01 | Cilag Gmbh International | Analyte test strip with electrically distinguishable divided electrode |
EP2615976B1 (en) * | 2010-09-13 | 2019-07-24 | Lifescan Scotland Limited | Analyte measurement method and system with hematocrit compensation |
BR112013016911A2 (en) * | 2010-12-31 | 2020-09-24 | Cilag Gmbh International | systems and methods for measuring high-precision analyte |
WO2012118784A1 (en) | 2011-02-28 | 2012-09-07 | Institute For Molecular Medicine, Inc. | Method and apparatus for measuring oxidation-reduction potential |
WO2012133633A1 (en) * | 2011-03-29 | 2012-10-04 | 株式会社テクノメデイカ | Disposable lysine sensor |
TWI427291B (en) * | 2011-07-06 | 2014-02-21 | Bionime Corp | Method for operating a measurement of a sample on an electrochemical test strip |
HK1207415A1 (en) | 2012-04-19 | 2016-01-29 | Aytu Biosciences, Inc. | Multiple layer gel |
JP2013242171A (en) * | 2012-05-18 | 2013-12-05 | Tanita Corp | Concentration measuring apparatus |
TWI513978B (en) | 2012-06-08 | 2015-12-21 | Hmd Biomedical Inc | Test strip, detecting device and detecting method |
US8877023B2 (en) * | 2012-06-21 | 2014-11-04 | Lifescan Scotland Limited | Electrochemical-based analytical test strip with intersecting sample-receiving chambers |
US20130341207A1 (en) * | 2012-06-21 | 2013-12-26 | Lifescan Scotland Limited | Analytical test strip with capillary sample-receiving chambers separated by stop junctions |
US9128038B2 (en) * | 2012-06-21 | 2015-09-08 | Lifescan Scotland Limited | Analytical test strip with capillary sample-receiving chambers separated by a physical barrier island |
GB2505694B (en) * | 2012-09-07 | 2017-03-22 | Lifescan Scotland Ltd | Electrochemical-based analytical test strip with bare interferent electrodes |
EP2885636B1 (en) | 2012-10-23 | 2018-02-14 | Aytu BioScience, Inc. | Methods and systems for measuring oxidation-reduction potential of a biological sample |
US9244036B2 (en) | 2012-11-16 | 2016-01-26 | Cilag Gmbh International | System and method for determination of a concentration of at least one interfering substance and correction of glucose concentration based on the concentration of the interfering substance |
TWI493186B (en) * | 2013-02-08 | 2015-07-21 | Hmd Biomedical Inc | Test strip, detecting device and detection method |
US9121050B2 (en) | 2013-03-15 | 2015-09-01 | American Sterilizer Company | Non-enzyme based detection method for electronic monitoring of biological indicator |
US8858884B2 (en) | 2013-03-15 | 2014-10-14 | American Sterilizer Company | Coupled enzyme-based method for electronic monitoring of biological indicator |
JP5813171B2 (en) * | 2013-05-02 | 2015-11-17 | アークレイ株式会社 | Analytical tool, manufacturing method thereof, and measuring device using the same |
GB2514846B (en) * | 2013-06-07 | 2015-09-30 | Lifescan Scotland Ltd | Electrochemical-based analytical test strip with a soluble electrochemically-active coating opposite a bare electrode |
GB2518165B (en) * | 2013-09-11 | 2016-04-27 | Cilag Gmbh Int | Electrochemical-based analytical test strip with ultra-thin discontinuous metal layer |
US20150068893A1 (en) * | 2013-09-12 | 2015-03-12 | Joinsoon Medical Technology Co., Ltd. | Biosensor test strip for biosensor test device |
JP6404681B2 (en) * | 2013-11-08 | 2018-10-10 | アークレイ株式会社 | Measuring apparatus and measuring method |
US20150176049A1 (en) | 2013-12-23 | 2015-06-25 | Cilag Gmbh International | Determining usability of analytical test strip |
US20170102382A1 (en) | 2014-07-25 | 2017-04-13 | Becton, Dickinson And Company | Analyte test strip assays, and test strips and kits for use in practicing the same |
US10060907B2 (en) | 2014-08-22 | 2018-08-28 | Roche Diagnostic Operations, Inc. | Redoxindicators |
ES2756714T3 (en) * | 2014-08-25 | 2020-04-27 | Hoffmann La Roche | Two electrode test strip to compensate for interference |
GB201419472D0 (en) | 2014-10-31 | 2014-12-17 | Inside Biometrics Ltd | Method of using and electrochemical device |
US20160187291A1 (en) * | 2014-12-31 | 2016-06-30 | Nipro Diagnostics, Inc. | Glucose test strip with interference correction |
US11828660B2 (en) * | 2015-05-10 | 2023-11-28 | Jp Laboratories, Inc. | UV cured indicating devices |
SI3220137T1 (en) | 2016-03-14 | 2019-05-31 | F. Hoffmann-La Roche Ag | Method for detecting an interferent contribution in a biosensor |
CN112698021B (en) * | 2016-12-23 | 2024-09-20 | 雷迪奥米特医学公司 | Multiple use sensor assembly for body fluids |
WO2019006413A1 (en) * | 2017-06-30 | 2019-01-03 | Abbott Diabetes Care | Method and apparatus for analyte detection using an electrochemical biosensor |
US10107776B1 (en) | 2017-11-21 | 2018-10-23 | Uxn Co., Ltd. | Glucose-sensing device with maltose blocking layer |
KR102755066B1 (en) * | 2017-12-15 | 2025-01-21 | 주식회사 유엑스엔 | Colloid with a nanoporous structure and device and system for non-enzymatic glucose-sensing |
CN109270145B (en) | 2018-11-20 | 2021-09-17 | 三诺生物传感股份有限公司 | Method for testing electrochemical test strip with double electrodes |
CN110082418B (en) * | 2019-05-27 | 2021-10-15 | 三诺生物传感股份有限公司 | Uric acid electrochemical measurement method |
CN112067604B (en) * | 2019-08-01 | 2023-01-10 | 杭州博拓生物科技股份有限公司 | Detection device |
CN112294320B (en) | 2019-08-02 | 2024-06-11 | 华广生技股份有限公司 | Implantable miniature biosensor |
TWI747410B (en) | 2019-08-02 | 2021-11-21 | 華廣生技股份有限公司 | Manufacturing method of implanted miniature biological sensor |
CN115867196A (en) * | 2020-07-08 | 2023-03-28 | 雅培糖尿病护理公司 | Analyte sensors featuring enhancements for reducing interference signals |
ES2915406B2 (en) * | 2020-12-21 | 2024-03-14 | Bioquochem S L | METHOD FOR MEASURING A CONCENTRATION OF AN ANALYTICAL COMPOUND OR AN ENZYMATIC ACTIVITY IN A COMPLEX SAMPLE BY SELECTIVELY QUANTIFYING HYDROGEN PEROXIDE |
CN115670453A (en) * | 2021-07-22 | 2023-02-03 | 华广生技股份有限公司 | Miniature Biosensor and Its Sensing Structure |
DE102022107214B4 (en) | 2022-03-28 | 2024-07-18 | Senslab - Gesellschaft Zur Entwicklung Und Herstellung Bioelektrochemischer Sensoren Mbh | Method and sensor for determining a plasma-related analyte concentration in whole blood |
US20230314340A1 (en) * | 2022-03-29 | 2023-10-05 | Medtronic, Inc. | Noise reduction for sensor apparatus |
IN202311040216A (en) * | 2023-06-13 | 2023-07-21 | ||
IN202311040523A (en) * | 2023-06-14 | 2023-07-28 | ||
US20250213152A1 (en) * | 2023-07-31 | 2025-07-03 | Abbott Diabetes Care Inc. | Background interference mitigation for high sensitivity ketone sensing |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431004A (en) * | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
US4655880A (en) * | 1983-08-01 | 1987-04-07 | Case Western Reserve University | Apparatus and method for sensing species, substances and substrates using oxidase |
US5298146A (en) * | 1991-11-08 | 1994-03-29 | Bayer Aktiengesellschaft | Device for the simultaneous detection of dissimilar gas components |
US5354447A (en) * | 1991-12-12 | 1994-10-11 | Kyoto Daiichi Kagaku Co., Ltd. | Biosensor and method of quantitative analysis using the same |
US5582697A (en) * | 1995-03-17 | 1996-12-10 | Matsushita Electric Industrial Co., Ltd. | Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same |
US5592551A (en) * | 1992-12-01 | 1997-01-07 | Scientific-Atlanta, Inc. | Method and apparatus for providing interactive electronic programming guide |
US5628890A (en) * | 1995-09-27 | 1997-05-13 | Medisense, Inc. | Electrochemical sensor |
US5650062A (en) * | 1995-03-17 | 1997-07-22 | Matsushita Electric Industrial Co., Ltd. | Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same |
US5653918A (en) * | 1996-01-11 | 1997-08-05 | E. I. Du Pont De Nemours And Company | Flexible thick film conductor composition |
US5708247A (en) * | 1996-02-14 | 1998-01-13 | Selfcare, Inc. | Disposable glucose test strips, and methods and compositions for making same |
US5830343A (en) * | 1994-07-11 | 1998-11-03 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Electrochemical analysis process |
US5985116A (en) * | 1996-12-24 | 1999-11-16 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US6048051A (en) * | 1996-10-16 | 2000-04-11 | Samsung Electronics Co., Ltd. | Ink-jet printing method and ink-jet printing apparatus using dielectric migration force |
US6212417B1 (en) * | 1998-08-26 | 2001-04-03 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US6258229B1 (en) * | 1999-06-02 | 2001-07-10 | Handani Winarta | Disposable sub-microliter volume sensor and method of making |
US6287451B1 (en) * | 1999-06-02 | 2001-09-11 | Handani Winarta | Disposable sensor and method of making |
US6340428B1 (en) * | 1998-04-02 | 2002-01-22 | Matsushita Electric Industrial Co., Inc. | Device and method for determining the concentration of a substrate |
US20020092612A1 (en) * | 2000-03-28 | 2002-07-18 | Davies Oliver William Hardwicke | Rapid response glucose sensor |
US20020157947A1 (en) * | 2001-03-23 | 2002-10-31 | Craig Rappin | Electrochemical sensor and method thereof |
US20020168290A1 (en) * | 2002-05-09 | 2002-11-14 | Yuzhakov Vadim V. | Physiological sample collection devices and methods of using the same |
US6540891B1 (en) * | 1998-05-08 | 2003-04-01 | Abbott Laboratories | Test strip |
US6599406B1 (en) * | 1997-07-22 | 2003-07-29 | Kyoto Daiichi Kagaku Co., Ltd. | Concentration measuring apparatus, test strip for the concentration measuring apparatus, biosensor system and method for forming terminal on the test strip |
US6730200B1 (en) * | 1999-06-18 | 2004-05-04 | Abbott Laboratories | Electrochemical sensor for analysis of liquid samples |
US20040120848A1 (en) * | 2002-12-20 | 2004-06-24 | Maria Teodorczyk | Method for manufacturing a sterilized and calibrated biosensor-based medical device |
US6881322B2 (en) * | 2000-01-25 | 2005-04-19 | Matsushita Electric Industrial Co., Ltd. | Measuring device using biosensor and biosenor used for it, and dedicated standard liquid |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US565062A (en) * | 1896-08-04 | Samuel l | ||
US4233031A (en) * | 1978-12-11 | 1980-11-11 | Environmental Sciences Associates, Inc. | Electrochemical testing system and method |
JPS613048A (en) * | 1984-06-18 | 1986-01-09 | Matsushita Electric Works Ltd | Measurement using biosensor |
JPH02501162A (en) * | 1987-08-28 | 1990-04-19 | ベツクマン・インダストリアル・コーポレーシヨン | Electrochemical cell noise reduction method |
WO1989009397A1 (en) * | 1988-03-31 | 1989-10-05 | Matsushita Electric Industrial Co., Ltd. | Biosensor and process for its production |
FR2661548B1 (en) * | 1990-04-30 | 1992-07-17 | Telemecanique | LOCKING INVERTER CONTACTOR APPARATUS. |
JPH04240558A (en) * | 1991-01-25 | 1992-08-27 | Sumitomo Metal Ind Ltd | enzyme electrode |
JP2960265B2 (en) * | 1991-10-18 | 1999-10-06 | 松下電器産業株式会社 | Biosensor and measurement method using the same |
JP2658769B2 (en) * | 1991-10-21 | 1997-09-30 | 松下電器産業株式会社 | Biosensor |
ZA938555B (en) * | 1992-11-23 | 1994-08-02 | Lilly Co Eli | Technique to improve the performance of electrochemical sensors |
JPH09129236A (en) * | 1995-08-25 | 1997-05-16 | Furukawa Battery Co Ltd:The | Negative active material for lithium secondary battery and lithium secondary battery |
US5650052A (en) * | 1995-10-04 | 1997-07-22 | Edelstein; Sergio | Variable cell size collimator |
EP0906563A1 (en) * | 1996-06-17 | 1999-04-07 | Mercury Diagnostics Inc. | Electrochemical test device and related methods |
US5943263A (en) * | 1997-01-08 | 1999-08-24 | Micron Technology, Inc. | Apparatus and method for programming voltage protection in a non-volatile memory system |
WO1998035225A1 (en) * | 1997-02-06 | 1998-08-13 | E. Heller & Company | Small volume in vitro analyte sensor |
BR7700267U (en) * | 1997-03-20 | 1998-11-03 | Wahler Metalurgica Ltda | Integrated thermostat |
US6139718A (en) | 1997-03-25 | 2000-10-31 | Cygnus, Inc. | Electrode with improved signal to noise ratio |
US6046051A (en) * | 1997-06-27 | 2000-04-04 | Hemosense, Inc. | Method and device for measuring blood coagulation or lysis by viscosity changes |
CA2302447A1 (en) | 1997-09-05 | 1999-03-18 | Abbott Laboratories | Electrochemical sensor having equalized electrode areas |
JP3267907B2 (en) * | 1997-09-29 | 2002-03-25 | 松下電器産業株式会社 | Biosensor and Substrate Quantification Method Using It |
US6001239A (en) * | 1998-09-30 | 1999-12-14 | Mercury Diagnostics, Inc. | Membrane based electrochemical test device and related methods |
JP3267933B2 (en) * | 1998-01-27 | 2002-03-25 | 松下電器産業株式会社 | Substrate quantification method |
AU5683599A (en) | 1998-08-31 | 2000-03-21 | Cubus Corporation | Computer product for networking a document development system using message headers associated with message files |
US6338790B1 (en) * | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
JP3462401B2 (en) * | 1998-10-15 | 2003-11-05 | 日本電信電話株式会社 | Electrochemical detector |
JP5073129B2 (en) * | 1999-03-31 | 2012-11-14 | 株式会社日本触媒 | (Meth) acrylic acid purification method |
US6616819B1 (en) * | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
KR100445489B1 (en) * | 1999-11-15 | 2004-08-21 | 마츠시타 덴끼 산교 가부시키가이샤 | Biosensor, method of forming thin-film electrode, and method and apparatus for quantitative determination |
GB0005564D0 (en) | 2000-03-08 | 2000-05-03 | Inverness Medical Ltd | Measurjement of substances in liquid |
DZ3334A1 (en) | 2000-03-28 | 2001-10-04 | Diabetes Diagnostics Inc | FAST RESPONSE GLUCOSE ANALYZER |
JP2002055076A (en) * | 2000-09-08 | 2002-02-20 | Nec Corp | Electrochemical sensor |
GB0030929D0 (en) | 2000-12-19 | 2001-01-31 | Inverness Medical Ltd | Analyte measurement |
JP3972063B2 (en) * | 2001-01-17 | 2007-09-05 | アークレイ株式会社 | Quantitative analysis method and quantitative analysis apparatus using sensor |
JP3672099B2 (en) * | 2001-06-14 | 2005-07-13 | 松下電器産業株式会社 | Biosensor |
DE10158420A1 (en) | 2001-11-29 | 2003-06-12 | Basf Ag | Adhesive containing glycidyl (meth) acrylate |
US6837976B2 (en) * | 2002-04-19 | 2005-01-04 | Nova Biomedical Corporation | Disposable sensor with enhanced sample port inlet |
DE10218828A1 (en) | 2002-04-26 | 2003-11-06 | Siemens Ag | Mobile RF device with transmission power limitation, can be set to maximum transmission power via mobilephone menu with user personally selecting maximum acceptable radiative loading level |
KR100485671B1 (en) * | 2002-09-30 | 2005-04-27 | 주식회사 인포피아 | A measuring instrument for biosensor |
EP1586222B1 (en) | 2002-10-30 | 2010-11-24 | Lifescan Scotland Ltd | Apparatus and method for controlling registration of print steps in a continuous process for the manufacture of electrochemical sensors |
US20040149578A1 (en) | 2003-01-30 | 2004-08-05 | Chun-Mu Huang | Method for manufacturing electrochemical sensor and structure thereof |
US7132041B2 (en) | 2003-02-11 | 2006-11-07 | Bayer Healthcare Llc | Methods of determining the concentration of an analyte in a fluid test sample |
US7462265B2 (en) * | 2003-06-06 | 2008-12-09 | Lifescan, Inc. | Reduced volume electrochemical sensor |
CA2543797C (en) * | 2003-10-31 | 2013-01-22 | Lifescan Scotland Limited | A method of reducing interferences in an electrochemical sensor using two different applied potentials |
US7655119B2 (en) * | 2003-10-31 | 2010-02-02 | Lifescan Scotland Limited | Meter for use in an improved method of reducing interferences in an electrochemical sensor using two different applied potentials |
US7875461B2 (en) * | 2007-07-24 | 2011-01-25 | Lifescan Scotland Limited | Test strip and connector |
-
2004
- 2004-10-29 CA CA2543797A patent/CA2543797C/en not_active Expired - Fee Related
- 2004-10-29 AU AU2004288011A patent/AU2004288011A1/en not_active Abandoned
- 2004-10-29 WO PCT/GB2004/004599 patent/WO2005045417A1/en not_active Application Discontinuation
- 2004-10-29 US US10/976,489 patent/US20050133368A1/en not_active Abandoned
- 2004-10-29 CA CA2551058A patent/CA2551058C/en not_active Expired - Fee Related
- 2004-10-29 JP JP2006537431A patent/JP2007514928A/en active Pending
- 2004-10-29 WO PCT/GB2004/004574 patent/WO2005045412A1/en active IP Right Grant
- 2004-10-29 ES ES04791625T patent/ES2327741T3/en not_active Expired - Lifetime
- 2004-10-29 US US10/977,292 patent/US20050114062A1/en not_active Abandoned
- 2004-10-29 PL PL04791611T patent/PL1678489T3/en unknown
- 2004-10-29 JP JP2006537432A patent/JP4652334B2/en not_active Expired - Fee Related
- 2004-10-29 CA CA002543961A patent/CA2543961A1/en not_active Abandoned
- 2004-10-29 CA CA2543957A patent/CA2543957C/en not_active Expired - Lifetime
- 2004-10-29 DK DK04769041T patent/DK1685393T3/en active
- 2004-10-29 PT PT04791611T patent/PT1678489E/en unknown
- 2004-10-29 WO PCT/GB2004/004594 patent/WO2005045415A1/en active Application Filing
- 2004-10-29 ES ES04791630T patent/ES2343184T3/en not_active Expired - Lifetime
- 2004-10-29 JP JP2006537429A patent/JP4694498B2/en not_active Expired - Fee Related
- 2004-10-29 EP EP04791625A patent/EP1678490B1/en not_active Expired - Lifetime
- 2004-10-29 DK DK04791611T patent/DK1678489T3/en active
- 2004-10-29 KR KR1020067010640A patent/KR20070027496A/en not_active Withdrawn
- 2004-10-29 WO PCT/GB2004/004598 patent/WO2005045416A1/en not_active Application Discontinuation
- 2004-10-29 PT PT04769041T patent/PT1685393E/en unknown
- 2004-10-29 EP EP04791630A patent/EP1678491B1/en not_active Expired - Lifetime
- 2004-10-29 AU AU2004288012A patent/AU2004288012B2/en not_active Ceased
- 2004-10-29 SG SG200702868-1A patent/SG131942A1/en unknown
- 2004-10-29 AU AU2004288013A patent/AU2004288013A1/en not_active Abandoned
- 2004-10-29 ES ES04791611T patent/ES2285536T3/en not_active Expired - Lifetime
- 2004-10-29 DE DE602004006148T patent/DE602004006148T2/en not_active Expired - Lifetime
- 2004-10-29 SG SG200702859-0A patent/SG131941A1/en unknown
- 2004-10-29 DE DE602004021835T patent/DE602004021835D1/en not_active Expired - Lifetime
- 2004-10-29 US US10/977,154 patent/US7618522B2/en not_active Expired - Fee Related
- 2004-10-29 DE DE602004004929T patent/DE602004004929T2/en not_active Expired - Lifetime
- 2004-10-29 KR KR1020067010291A patent/KR101201245B1/en not_active Expired - Fee Related
- 2004-10-29 JP JP2006537434A patent/JP2007514930A/en active Pending
- 2004-10-29 EP EP04791611A patent/EP1678489B1/en not_active Expired - Lifetime
- 2004-10-29 AT AT04791630T patent/ATE460661T1/en not_active IP Right Cessation
- 2004-10-29 EP EP04791634A patent/EP1678493A1/en not_active Withdrawn
- 2004-10-29 AU AU2004288014A patent/AU2004288014A1/en not_active Abandoned
- 2004-10-29 ES ES04769041T patent/ES2282898T3/en not_active Expired - Lifetime
- 2004-10-29 DK DK04791625T patent/DK1678490T3/en active
- 2004-10-29 AT AT04791611T patent/ATE360816T1/en not_active IP Right Cessation
- 2004-10-29 AU AU2004288008A patent/AU2004288008B2/en not_active Ceased
- 2004-10-29 AU AU2004288004A patent/AU2004288004B2/en not_active Ceased
- 2004-10-29 EP EP04769041A patent/EP1685393B1/en not_active Expired - Lifetime
- 2004-10-29 PL PL04791625T patent/PL1678490T3/en unknown
- 2004-10-29 AT AT04791625T patent/ATE435419T1/en active
- 2004-10-29 CA CA002544424A patent/CA2544424A1/en not_active Abandoned
- 2004-10-29 JP JP2006537435A patent/JP2007514931A/en active Pending
- 2004-10-29 KR KR1020067010636A patent/KR101179998B1/en not_active Expired - Fee Related
- 2004-10-29 US US10/977,086 patent/US20050139489A1/en not_active Abandoned
- 2004-10-29 US US10/977,316 patent/US20050139469A1/en not_active Abandoned
- 2004-10-29 WO PCT/GB2004/004588 patent/WO2005045413A1/en active Application Filing
- 2004-10-29 AT AT04769041T patent/ATE354796T1/en not_active IP Right Cessation
- 2004-10-29 KR KR1020067010641A patent/KR20070027497A/en not_active Withdrawn
- 2004-10-29 EP EP04791633A patent/EP1678492A1/en not_active Withdrawn
- 2004-10-29 DE DE602004025960T patent/DE602004025960D1/en not_active Expired - Lifetime
- 2004-10-29 US US10/577,586 patent/US7653492B2/en not_active Expired - Lifetime
- 2004-10-29 CA CA002543802A patent/CA2543802A1/en not_active Abandoned
- 2004-10-29 JP JP2006537423A patent/JP4611313B2/en not_active Expired - Fee Related
- 2004-10-29 PL PL04769041T patent/PL1685393T3/en unknown
- 2004-10-29 WO PCT/GB2004/004592 patent/WO2005045414A1/en active IP Right Grant
- 2004-10-29 KR KR1020067010292A patent/KR101092350B1/en not_active Expired - Fee Related
-
2006
- 2006-04-30 IL IL175323A patent/IL175323A0/en unknown
- 2006-04-30 IL IL175322A patent/IL175322A0/en active IP Right Grant
- 2006-04-30 IL IL175320A patent/IL175320A0/en unknown
- 2006-04-30 IL IL175324A patent/IL175324A0/en unknown
- 2006-04-30 IL IL175325A patent/IL175325A0/en unknown
- 2006-04-30 IL IL175321A patent/IL175321A0/en unknown
-
2009
- 2009-10-06 US US12/574,469 patent/US20100018878A1/en not_active Abandoned
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431004A (en) * | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
US4655880A (en) * | 1983-08-01 | 1987-04-07 | Case Western Reserve University | Apparatus and method for sensing species, substances and substrates using oxidase |
US5298146A (en) * | 1991-11-08 | 1994-03-29 | Bayer Aktiengesellschaft | Device for the simultaneous detection of dissimilar gas components |
US5354447A (en) * | 1991-12-12 | 1994-10-11 | Kyoto Daiichi Kagaku Co., Ltd. | Biosensor and method of quantitative analysis using the same |
US5592551A (en) * | 1992-12-01 | 1997-01-07 | Scientific-Atlanta, Inc. | Method and apparatus for providing interactive electronic programming guide |
US5830343A (en) * | 1994-07-11 | 1998-11-03 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Electrochemical analysis process |
US5582697A (en) * | 1995-03-17 | 1996-12-10 | Matsushita Electric Industrial Co., Ltd. | Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same |
US5650062A (en) * | 1995-03-17 | 1997-07-22 | Matsushita Electric Industrial Co., Ltd. | Biosensor, and a method and a device for quantifying a substrate in a sample liquid using the same |
US5628890A (en) * | 1995-09-27 | 1997-05-13 | Medisense, Inc. | Electrochemical sensor |
US5653918A (en) * | 1996-01-11 | 1997-08-05 | E. I. Du Pont De Nemours And Company | Flexible thick film conductor composition |
US5708247A (en) * | 1996-02-14 | 1998-01-13 | Selfcare, Inc. | Disposable glucose test strips, and methods and compositions for making same |
US6048051A (en) * | 1996-10-16 | 2000-04-11 | Samsung Electronics Co., Ltd. | Ink-jet printing method and ink-jet printing apparatus using dielectric migration force |
US5985116A (en) * | 1996-12-24 | 1999-11-16 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US6599406B1 (en) * | 1997-07-22 | 2003-07-29 | Kyoto Daiichi Kagaku Co., Ltd. | Concentration measuring apparatus, test strip for the concentration measuring apparatus, biosensor system and method for forming terminal on the test strip |
US6790327B2 (en) * | 1998-04-02 | 2004-09-14 | Matsushita Electric Industrial Co., Ltd. | Device and method for determining the concentration of a substrate |
US6340428B1 (en) * | 1998-04-02 | 2002-01-22 | Matsushita Electric Industrial Co., Inc. | Device and method for determining the concentration of a substrate |
US6540891B1 (en) * | 1998-05-08 | 2003-04-01 | Abbott Laboratories | Test strip |
US6212417B1 (en) * | 1998-08-26 | 2001-04-03 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US6287451B1 (en) * | 1999-06-02 | 2001-09-11 | Handani Winarta | Disposable sensor and method of making |
US6258229B1 (en) * | 1999-06-02 | 2001-07-10 | Handani Winarta | Disposable sub-microliter volume sensor and method of making |
US6730200B1 (en) * | 1999-06-18 | 2004-05-04 | Abbott Laboratories | Electrochemical sensor for analysis of liquid samples |
US6881322B2 (en) * | 2000-01-25 | 2005-04-19 | Matsushita Electric Industrial Co., Ltd. | Measuring device using biosensor and biosenor used for it, and dedicated standard liquid |
US20020092612A1 (en) * | 2000-03-28 | 2002-07-18 | Davies Oliver William Hardwicke | Rapid response glucose sensor |
US20020157947A1 (en) * | 2001-03-23 | 2002-10-31 | Craig Rappin | Electrochemical sensor and method thereof |
US20020168290A1 (en) * | 2002-05-09 | 2002-11-14 | Yuzhakov Vadim V. | Physiological sample collection devices and methods of using the same |
US20030143113A2 (en) * | 2002-05-09 | 2003-07-31 | Lifescan, Inc. | Physiological sample collection devices and methods of using the same |
US20040120848A1 (en) * | 2002-12-20 | 2004-06-24 | Maria Teodorczyk | Method for manufacturing a sterilized and calibrated biosensor-based medical device |
Cited By (480)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9439589B2 (en) | 1997-03-04 | 2016-09-13 | Dexcom, Inc. | Device and method for determining analyte levels |
US8155723B2 (en) | 1997-03-04 | 2012-04-10 | Dexcom, Inc. | Device and method for determining analyte levels |
US7974672B2 (en) | 1997-03-04 | 2011-07-05 | Dexcom, Inc. | Device and method for determining analyte levels |
US7970448B2 (en) | 1997-03-04 | 2011-06-28 | Dexcom, Inc. | Device and method for determining analyte levels |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US8527025B1 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US9931067B2 (en) | 1997-03-04 | 2018-04-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US7901354B2 (en) | 1997-03-04 | 2011-03-08 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US8676288B2 (en) | 1997-03-04 | 2014-03-18 | Dexcom, Inc. | Device and method for determining analyte levels |
US7835777B2 (en) | 1997-03-04 | 2010-11-16 | Dexcom, Inc. | Device and method for determining analyte levels |
US7792562B2 (en) | 1997-03-04 | 2010-09-07 | Dexcom, Inc. | Device and method for determining analyte levels |
US8923947B2 (en) | 1997-03-04 | 2014-12-30 | Dexcom, Inc. | Device and method for determining analyte levels |
US7771352B2 (en) | 1997-03-04 | 2010-08-10 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9339223B2 (en) | 1997-03-04 | 2016-05-17 | Dexcom, Inc. | Device and method for determining analyte levels |
US7885699B2 (en) | 1998-04-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8622906B2 (en) | 1998-04-30 | 2014-01-07 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8226555B2 (en) | 1998-04-30 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9326714B2 (en) | 1998-04-30 | 2016-05-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8177716B2 (en) | 1998-04-30 | 2012-05-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8175673B2 (en) | 1998-04-30 | 2012-05-08 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8226558B2 (en) | 1998-04-30 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9072477B2 (en) | 1998-04-30 | 2015-07-07 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066694B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066697B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9042953B2 (en) | 1998-04-30 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9011331B2 (en) | 1998-04-30 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8226557B2 (en) | 1998-04-30 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9014773B2 (en) | 1998-04-30 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8162829B2 (en) | 1998-04-30 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8231532B2 (en) | 1998-04-30 | 2012-07-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8880137B2 (en) | 1998-04-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8235896B2 (en) | 1998-04-30 | 2012-08-07 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8840553B2 (en) | 1998-04-30 | 2014-09-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8255031B2 (en) | 1998-04-30 | 2012-08-28 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8774887B2 (en) | 1998-04-30 | 2014-07-08 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8744545B2 (en) | 1998-04-30 | 2014-06-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8738109B2 (en) | 1998-04-30 | 2014-05-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8734348B2 (en) | 1998-04-30 | 2014-05-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8734346B2 (en) | 1998-04-30 | 2014-05-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8260392B2 (en) | 1998-04-30 | 2012-09-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7860544B2 (en) | 1998-04-30 | 2010-12-28 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8672844B2 (en) | 1998-04-30 | 2014-03-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8265726B2 (en) | 1998-04-30 | 2012-09-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8670815B2 (en) | 1998-04-30 | 2014-03-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8275439B2 (en) | 1998-04-30 | 2012-09-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7869853B1 (en) | 1998-04-30 | 2011-01-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8273022B2 (en) | 1998-04-30 | 2012-09-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8224413B2 (en) | 1998-04-30 | 2012-07-17 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8666469B2 (en) | 1998-04-30 | 2014-03-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8660627B2 (en) | 1998-04-30 | 2014-02-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8287454B2 (en) | 1998-04-30 | 2012-10-16 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8649841B2 (en) | 1998-04-30 | 2014-02-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8306598B2 (en) | 1998-04-30 | 2012-11-06 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8641619B2 (en) | 1998-04-30 | 2014-02-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8617071B2 (en) | 1998-04-30 | 2013-12-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8612159B2 (en) | 1998-04-30 | 2013-12-17 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8597189B2 (en) | 1998-04-30 | 2013-12-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346336B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8353829B2 (en) | 1998-04-30 | 2013-01-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8357091B2 (en) | 1998-04-30 | 2013-01-22 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8366614B2 (en) | 1998-04-30 | 2013-02-05 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8473021B2 (en) | 1998-04-30 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8409131B2 (en) | 1998-04-30 | 2013-04-02 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10478108B2 (en) | 1998-04-30 | 2019-11-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8372005B2 (en) | 1998-04-30 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8391945B2 (en) | 1998-04-30 | 2013-03-05 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8380273B2 (en) | 1998-04-30 | 2013-02-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9011332B2 (en) | 2001-01-02 | 2015-04-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9610034B2 (en) | 2001-01-02 | 2017-04-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8668645B2 (en) | 2001-01-02 | 2014-03-11 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8652043B2 (en) | 2001-01-02 | 2014-02-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9498159B2 (en) | 2001-01-02 | 2016-11-22 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US7310543B2 (en) | 2001-03-26 | 2007-12-18 | Kumetrix, Inc. | Silicon microprobe with integrated biosensor |
US20080097171A1 (en) * | 2001-03-26 | 2008-04-24 | Wilson Smart | Silicon microprobe with integrated biosensor |
US20020137998A1 (en) * | 2001-03-26 | 2002-09-26 | Wilson Smart | Silicon microprobe with integrated biosensor |
US20080009767A1 (en) * | 2001-07-20 | 2008-01-10 | Roche Diagnostics Operations, Inc. | System for withdrawing small amounts of body fluid |
US8388552B2 (en) | 2001-07-20 | 2013-03-05 | Roche Diagnostics Operations, Inc. | System for withdrawing small amounts of body fluid |
US7993284B2 (en) | 2001-07-20 | 2011-08-09 | Roche Diagnostics Operations, Inc. | System for withdrawing small amounts of body fluid |
US7288073B2 (en) | 2001-07-20 | 2007-10-30 | Roche Diagnostics Operations, Inc. | System for withdrawing small amounts of body fluid |
US8821413B2 (en) | 2001-07-20 | 2014-09-02 | Roche Diagnostics Operations, Inc. | System for withdrawing small amounts of body fluid |
US20030018282A1 (en) * | 2001-07-20 | 2003-01-23 | Carlo Effenhauser | System for withdrawing small amounts of body fluid |
US9804114B2 (en) | 2001-07-27 | 2017-10-31 | Dexcom, Inc. | Sensor head for use with implantable devices |
US8509871B2 (en) | 2001-07-27 | 2013-08-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US9328371B2 (en) | 2001-07-27 | 2016-05-03 | Dexcom, Inc. | Sensor head for use with implantable devices |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8543184B2 (en) | 2002-05-22 | 2013-09-24 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8064977B2 (en) | 2002-05-22 | 2011-11-22 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US9549693B2 (en) | 2002-05-22 | 2017-01-24 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US10052051B2 (en) | 2002-05-22 | 2018-08-21 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US11020026B2 (en) | 2002-05-22 | 2021-06-01 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8052926B2 (en) | 2002-12-27 | 2011-11-08 | Roche Diagnostics Operations, Inc. | Method for manufacturing a sterilized lancet integrated biosensor |
US20090010802A1 (en) * | 2002-12-27 | 2009-01-08 | Abner David Joseph | Method for manufacturing a sterilized lancet integrated biosensor |
US7881763B2 (en) | 2003-04-04 | 2011-02-01 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US9993186B2 (en) | 2003-07-25 | 2018-06-12 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US8909314B2 (en) | 2003-07-25 | 2014-12-09 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US8255032B2 (en) | 2003-07-25 | 2012-08-28 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US8255033B2 (en) | 2003-07-25 | 2012-08-28 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US8255030B2 (en) | 2003-07-25 | 2012-08-28 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9597027B2 (en) | 2003-07-25 | 2017-03-21 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US7896809B2 (en) | 2003-07-25 | 2011-03-01 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10610140B2 (en) | 2003-07-25 | 2020-04-07 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US20060189856A1 (en) * | 2003-07-25 | 2006-08-24 | James Petisce | Oxygen enhancing membrane systems for implantable devices |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7828728B2 (en) | 2003-07-25 | 2010-11-09 | Dexcom, Inc. | Analyte sensor |
US8285354B2 (en) | 2003-08-01 | 2012-10-09 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7797028B2 (en) | 2003-08-01 | 2010-09-14 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8788007B2 (en) | 2003-08-01 | 2014-07-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8788008B2 (en) | 2003-08-01 | 2014-07-22 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8774888B2 (en) | 2003-08-01 | 2014-07-08 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8771187B2 (en) | 2003-08-01 | 2014-07-08 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8915849B2 (en) | 2003-08-01 | 2014-12-23 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7826981B2 (en) | 2003-08-01 | 2010-11-02 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7778680B2 (en) | 2003-08-01 | 2010-08-17 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US8700117B2 (en) | 2003-08-01 | 2014-04-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8801612B2 (en) | 2003-08-01 | 2014-08-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20100174167A1 (en) * | 2003-08-01 | 2010-07-08 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8808182B2 (en) | 2003-08-01 | 2014-08-19 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US20100161269A1 (en) * | 2003-08-01 | 2010-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8060173B2 (en) | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8676287B2 (en) | 2003-08-01 | 2014-03-18 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8290562B2 (en) | 2003-08-01 | 2012-10-16 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8788006B2 (en) | 2003-08-01 | 2014-07-22 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US9895089B2 (en) | 2003-08-01 | 2018-02-20 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7914450B2 (en) | 2003-08-01 | 2011-03-29 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8622905B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8052601B2 (en) | 2003-08-01 | 2011-11-08 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8311749B2 (en) | 2003-08-01 | 2012-11-13 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8321149B2 (en) | 2003-08-01 | 2012-11-27 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8332008B2 (en) | 2003-08-01 | 2012-12-11 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8588882B2 (en) | 2003-08-01 | 2013-11-19 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8548553B2 (en) | 2003-08-01 | 2013-10-01 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7925321B2 (en) | 2003-08-01 | 2011-04-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7933639B2 (en) | 2003-08-01 | 2011-04-26 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8000901B2 (en) | 2003-08-01 | 2011-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8206297B2 (en) | 2003-08-01 | 2012-06-26 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7955261B2 (en) | 2003-08-01 | 2011-06-07 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7986986B2 (en) | 2003-08-01 | 2011-07-26 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US10786185B2 (en) | 2003-08-01 | 2020-09-29 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8442610B2 (en) | 2003-08-01 | 2013-05-14 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7979104B2 (en) | 2003-08-01 | 2011-07-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8428679B2 (en) | 2003-08-01 | 2013-04-23 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8394021B2 (en) | 2003-08-01 | 2013-03-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7959569B2 (en) | 2003-08-01 | 2011-06-14 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US9510782B2 (en) | 2003-08-22 | 2016-12-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8672845B2 (en) | 2003-08-22 | 2014-03-18 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US8292810B2 (en) | 2003-08-22 | 2012-10-23 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9724045B1 (en) | 2003-08-22 | 2017-08-08 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8843187B2 (en) | 2003-08-22 | 2014-09-23 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8195265B2 (en) | 2003-08-22 | 2012-06-05 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8812073B2 (en) | 2003-08-22 | 2014-08-19 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8435179B2 (en) | 2003-08-22 | 2013-05-07 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8229536B2 (en) | 2003-08-22 | 2012-07-24 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9750460B2 (en) | 2003-08-22 | 2017-09-05 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9649069B2 (en) | 2003-08-22 | 2017-05-16 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8657747B2 (en) | 2003-08-22 | 2014-02-25 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US8167801B2 (en) | 2003-08-22 | 2012-05-01 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7998071B2 (en) | 2003-08-22 | 2011-08-16 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8790260B2 (en) | 2003-08-22 | 2014-07-29 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9585607B2 (en) | 2003-08-22 | 2017-03-07 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8233959B2 (en) | 2003-08-22 | 2012-07-31 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US8777853B2 (en) | 2003-08-22 | 2014-07-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8150488B2 (en) | 2003-08-22 | 2012-04-03 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8491474B2 (en) | 2003-08-22 | 2013-07-23 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8128562B2 (en) | 2003-08-22 | 2012-03-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8821400B2 (en) | 2003-08-22 | 2014-09-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8073520B2 (en) | 2003-08-22 | 2011-12-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8073519B2 (en) | 2003-08-22 | 2011-12-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8412301B2 (en) | 2003-08-22 | 2013-04-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8005525B2 (en) | 2003-08-22 | 2011-08-23 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US20050043598A1 (en) * | 2003-08-22 | 2005-02-24 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9427183B2 (en) | 2003-08-22 | 2016-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11589823B2 (en) | 2003-08-22 | 2023-02-28 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9420968B2 (en) | 2003-08-22 | 2016-08-23 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9149219B2 (en) | 2003-08-22 | 2015-10-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11559260B2 (en) | 2003-08-22 | 2023-01-24 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US8346338B2 (en) | 2003-08-22 | 2013-01-01 | Dexcom, Inc. | System and methods for replacing signal artifacts in a glucose sensor data stream |
US20100018878A1 (en) * | 2003-10-31 | 2010-01-28 | Lifescan Scotland Ltd. | Method of reducing interferences in an electrochemical sensor using two different applied potentials |
US7653492B2 (en) * | 2003-10-31 | 2010-01-26 | Lifescan Scotland Limited | Method of reducing the effect of direct interference current in an electrochemical test strip |
US7655119B2 (en) | 2003-10-31 | 2010-02-02 | Lifescan Scotland Limited | Meter for use in an improved method of reducing interferences in an electrochemical sensor using two different applied potentials |
US20050183965A1 (en) * | 2003-10-31 | 2005-08-25 | Davies Oliver William H. | Method of reducing interferences in an electrochemical sensor using two different applied potentials |
US7618522B2 (en) | 2003-10-31 | 2009-11-17 | Lifescan Scotland Limited | Method of reducing interferences in an electrochemical sensor using two different applied potentials |
US20070276621A1 (en) * | 2003-10-31 | 2007-11-29 | Davies Oliver William H | Method of Reducing the Effect of Direct Interference Current in an Electrochemical Test Strip |
US20050109618A1 (en) * | 2003-10-31 | 2005-05-26 | Davies Oliver W.H. | Meter for use in an improved method of reducing interferences in an electrochemical sensor using two different applied potentials |
US7927274B2 (en) | 2003-11-19 | 2011-04-19 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US11564602B2 (en) | 2003-11-19 | 2023-01-31 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US9538946B2 (en) | 2003-11-19 | 2017-01-10 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US8282550B2 (en) | 2003-11-19 | 2012-10-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US8911369B2 (en) | 2003-12-05 | 2014-12-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7917186B2 (en) | 2003-12-05 | 2011-03-29 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US8386004B2 (en) | 2003-12-05 | 2013-02-26 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US9579053B2 (en) | 2003-12-05 | 2017-02-28 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8160671B2 (en) | 2003-12-05 | 2012-04-17 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US8249684B2 (en) | 2003-12-05 | 2012-08-21 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US8483793B2 (en) | 2003-12-05 | 2013-07-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
USRE44695E1 (en) | 2003-12-05 | 2014-01-07 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10188333B2 (en) | 2003-12-05 | 2019-01-29 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US10299712B2 (en) | 2003-12-05 | 2019-05-28 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8428678B2 (en) | 2003-12-05 | 2013-04-23 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8929968B2 (en) | 2003-12-05 | 2015-01-06 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11000215B1 (en) | 2003-12-05 | 2021-05-11 | Dexcom, Inc. | Analyte sensor |
US7715893B2 (en) | 2003-12-05 | 2010-05-11 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US11020031B1 (en) | 2003-12-05 | 2021-06-01 | Dexcom, Inc. | Analyte sensor |
US9364173B2 (en) | 2003-12-09 | 2016-06-14 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8265725B2 (en) | 2003-12-09 | 2012-09-11 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US11638541B2 (en) | 2003-12-09 | 2023-05-02 | Dexconi, Inc. | Signal processing for continuous analyte sensor |
US10898113B2 (en) | 2003-12-09 | 2021-01-26 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8005524B2 (en) | 2003-12-09 | 2011-08-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9750441B2 (en) | 2003-12-09 | 2017-09-05 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8801610B2 (en) | 2003-12-09 | 2014-08-12 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9107623B2 (en) | 2003-12-09 | 2015-08-18 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8374667B2 (en) | 2003-12-09 | 2013-02-12 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8282549B2 (en) | 2003-12-09 | 2012-10-09 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9498155B2 (en) | 2003-12-09 | 2016-11-22 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8290561B2 (en) | 2003-12-09 | 2012-10-16 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9420965B2 (en) | 2003-12-09 | 2016-08-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9351668B2 (en) | 2003-12-09 | 2016-05-31 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8747315B2 (en) | 2003-12-09 | 2014-06-10 | Dexcom. Inc. | Signal processing for continuous analyte sensor |
US8257259B2 (en) | 2003-12-09 | 2012-09-04 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US9192328B2 (en) | 2003-12-09 | 2015-11-24 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8469886B2 (en) | 2003-12-09 | 2013-06-25 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8251906B2 (en) | 2003-12-09 | 2012-08-28 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8216139B2 (en) | 2003-12-09 | 2012-07-10 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8233958B2 (en) | 2003-12-09 | 2012-07-31 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8657745B2 (en) | 2003-12-09 | 2014-02-25 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8920401B2 (en) | 2004-02-26 | 2014-12-30 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US9155843B2 (en) | 2004-02-26 | 2015-10-13 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US10835672B2 (en) | 2004-02-26 | 2020-11-17 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US9050413B2 (en) | 2004-02-26 | 2015-06-09 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US12226617B2 (en) | 2004-02-26 | 2025-02-18 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8926585B2 (en) | 2004-02-26 | 2015-01-06 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8882741B2 (en) | 2004-02-26 | 2014-11-11 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8721585B2 (en) | 2004-02-26 | 2014-05-13 | Dex Com, Inc. | Integrated delivery device for continuous glucose sensor |
US12115357B2 (en) | 2004-02-26 | 2024-10-15 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US7976492B2 (en) | 2004-02-26 | 2011-07-12 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US10966609B2 (en) | 2004-02-26 | 2021-04-06 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US12102410B2 (en) | 2004-02-26 | 2024-10-01 | Dexcom, Inc | Integrated medicament delivery device for use with continuous analyte sensor |
US11246990B2 (en) | 2004-02-26 | 2022-02-15 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20090062633A1 (en) * | 2004-05-03 | 2009-03-05 | Dexcorn, Inc. | Implantable analyte sensor |
US10327638B2 (en) | 2004-05-03 | 2019-06-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US9833143B2 (en) | 2004-05-03 | 2017-12-05 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10918315B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US8812072B2 (en) | 2004-07-13 | 2014-08-19 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US8801611B2 (en) | 2004-07-13 | 2014-08-12 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10524703B2 (en) | 2004-07-13 | 2020-01-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8792954B2 (en) | 2004-07-13 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8229534B2 (en) | 2004-07-13 | 2012-07-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20100228109A1 (en) * | 2004-07-13 | 2010-09-09 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10314525B2 (en) | 2004-07-13 | 2019-06-11 | Dexcom, Inc. | Analyte sensor |
US8170803B2 (en) | 2004-07-13 | 2012-05-01 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11045120B2 (en) | 2004-07-13 | 2021-06-29 | Dexcom, Inc. | Analyte sensor |
US10709362B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US11026605B1 (en) | 2004-07-13 | 2021-06-08 | Dexcom, Inc. | Analyte sensor |
US8731630B2 (en) | 2004-07-13 | 2014-05-20 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8721545B2 (en) | 2004-07-13 | 2014-05-13 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11064917B2 (en) | 2004-07-13 | 2021-07-20 | Dexcom, Inc. | Analyte sensor |
US10709363B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US8690775B2 (en) | 2004-07-13 | 2014-04-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US7857760B2 (en) | 2004-07-13 | 2010-12-28 | Dexcom, Inc. | Analyte sensor |
US8280475B2 (en) | 2004-07-13 | 2012-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9986942B2 (en) | 2004-07-13 | 2018-06-05 | Dexcom, Inc. | Analyte sensor |
US8290560B2 (en) | 2004-07-13 | 2012-10-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9044199B2 (en) | 2004-07-13 | 2015-06-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10722152B2 (en) | 2004-07-13 | 2020-07-28 | Dexcom, Inc. | Analyte sensor |
US9055901B2 (en) | 2004-07-13 | 2015-06-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9060742B2 (en) | 2004-07-13 | 2015-06-23 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9833176B2 (en) | 2004-07-13 | 2017-12-05 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8663109B2 (en) | 2004-07-13 | 2014-03-04 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9078626B2 (en) | 2004-07-13 | 2015-07-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US9814414B2 (en) | 2004-07-13 | 2017-11-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7905833B2 (en) | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10993641B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10993642B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10980452B2 (en) | 2004-07-13 | 2021-04-20 | Dexcom, Inc. | Analyte sensor |
US8615282B2 (en) | 2004-07-13 | 2013-12-24 | Dexcom, Inc. | Analyte sensor |
US9801572B2 (en) | 2004-07-13 | 2017-10-31 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9775543B2 (en) | 2004-07-13 | 2017-10-03 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11883164B2 (en) | 2004-07-13 | 2024-01-30 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10932700B2 (en) | 2004-07-13 | 2021-03-02 | Dexcom, Inc. | Analyte sensor |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10799158B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US10799159B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US9668677B2 (en) | 2004-07-13 | 2017-06-06 | Dexcom, Inc. | Analyte sensor |
US8457708B2 (en) | 2004-07-13 | 2013-06-04 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8463350B2 (en) | 2004-07-13 | 2013-06-11 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10918314B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US8858434B2 (en) | 2004-07-13 | 2014-10-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10918313B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US9610031B2 (en) | 2004-07-13 | 2017-04-04 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8548551B2 (en) | 2004-07-13 | 2013-10-01 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7946984B2 (en) | 2004-07-13 | 2011-05-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8571625B2 (en) | 2004-07-13 | 2013-10-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9414777B2 (en) | 2004-07-13 | 2016-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8565849B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8475373B2 (en) | 2004-07-13 | 2013-07-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8825127B2 (en) | 2004-07-13 | 2014-09-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7949381B2 (en) | 2004-07-13 | 2011-05-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8792953B2 (en) | 2004-07-13 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20080242961A1 (en) * | 2004-07-13 | 2008-10-02 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8515516B2 (en) | 2004-07-13 | 2013-08-20 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10813576B2 (en) | 2004-07-13 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US10827956B2 (en) | 2004-07-13 | 2020-11-10 | Dexcom, Inc. | Analyte sensor |
US8515519B2 (en) | 2004-07-13 | 2013-08-20 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8483791B2 (en) | 2004-07-13 | 2013-07-09 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7935063B2 (en) | 2005-03-02 | 2011-05-03 | Roche Diagnostics Operations, Inc. | System and method for breaking a sterility seal to engage a lancet |
US7815579B2 (en) | 2005-03-02 | 2010-10-19 | Roche Diagnostics Operations, Inc. | Dynamic integrated lancing test strip with sterility cover |
US20060200045A1 (en) * | 2005-03-02 | 2006-09-07 | Roe Steven N | Dynamic integrated lancing test strip with sterility cover |
US20110000168A1 (en) * | 2005-03-02 | 2011-01-06 | Roe Steven N | Dynamic integrated lancing test strip with sterility cover |
US20070167869A1 (en) * | 2005-03-02 | 2007-07-19 | Roe Steven N | System and method for breaking a sterility seal to engage a lancet |
US20110178435A1 (en) * | 2005-03-02 | 2011-07-21 | Roe Steven N | System and method for breaking a sterility seal to engage a lancet |
US8921065B2 (en) * | 2005-03-04 | 2014-12-30 | Bayer Healthcare Llc | Reagent composition for electrochemical biosensors |
US20080199937A1 (en) * | 2005-03-04 | 2008-08-21 | Chu Amy H | Reagent Composition and Methods of Using and Forming the Same |
US10610102B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9078608B2 (en) | 2005-03-10 | 2015-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918316B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9220449B2 (en) | 2005-03-10 | 2015-12-29 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US8579816B2 (en) | 2005-03-10 | 2013-11-12 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10925524B2 (en) | 2005-03-10 | 2021-02-23 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US8611978B2 (en) | 2005-03-10 | 2013-12-17 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610137B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10743801B2 (en) | 2005-03-10 | 2020-08-18 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10898114B2 (en) | 2005-03-10 | 2021-01-26 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10856787B2 (en) | 2005-03-10 | 2020-12-08 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918318B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9314196B2 (en) | 2005-03-10 | 2016-04-19 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610136B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610135B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10709364B2 (en) | 2005-03-10 | 2020-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US8560037B2 (en) | 2005-03-10 | 2013-10-15 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10617336B2 (en) | 2005-03-10 | 2020-04-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11051726B2 (en) | 2005-03-10 | 2021-07-06 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US9918668B2 (en) | 2005-03-10 | 2018-03-20 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10716498B2 (en) | 2005-03-10 | 2020-07-21 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918317B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11000213B2 (en) | 2005-03-10 | 2021-05-11 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10624539B2 (en) | 2005-03-10 | 2020-04-21 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10300507B2 (en) | 2005-05-05 | 2019-05-28 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US10813577B2 (en) | 2005-06-21 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US10709332B2 (en) | 2005-06-21 | 2020-07-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10610103B2 (en) | 2005-06-21 | 2020-04-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8920319B2 (en) | 2005-11-01 | 2014-12-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10952652B2 (en) | 2005-11-01 | 2021-03-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9326716B2 (en) | 2005-11-01 | 2016-05-03 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10201301B2 (en) | 2005-11-01 | 2019-02-12 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10231654B2 (en) | 2005-11-01 | 2019-03-19 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11103165B2 (en) | 2005-11-01 | 2021-08-31 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11911151B1 (en) | 2005-11-01 | 2024-02-27 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11272867B2 (en) | 2005-11-01 | 2022-03-15 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8915850B2 (en) | 2005-11-01 | 2014-12-23 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11363975B2 (en) | 2005-11-01 | 2022-06-21 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US11399748B2 (en) | 2005-11-01 | 2022-08-02 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9078607B2 (en) | 2005-11-01 | 2015-07-14 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US10265000B2 (en) | 2006-01-17 | 2019-04-23 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US11191458B2 (en) | 2006-01-17 | 2021-12-07 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US11596332B2 (en) | 2006-01-17 | 2023-03-07 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US9724028B2 (en) | 2006-02-22 | 2017-08-08 | Dexcom, Inc. | Analyte sensor |
US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
US11432772B2 (en) | 2006-08-02 | 2022-09-06 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US11382539B2 (en) | 2006-10-04 | 2022-07-12 | Dexcom, Inc. | Analyte sensor |
WO2008042918A3 (en) * | 2006-10-04 | 2008-09-04 | Dexcom Inc | Dual electrode system for a continuous analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US11399745B2 (en) | 2006-10-04 | 2022-08-02 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US10349873B2 (en) | 2006-10-04 | 2019-07-16 | Dexcom, Inc. | Analyte sensor |
US9451908B2 (en) | 2006-10-04 | 2016-09-27 | Dexcom, Inc. | Analyte sensor |
US10136844B2 (en) | 2006-10-04 | 2018-11-27 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US9504413B2 (en) | 2006-10-04 | 2016-11-29 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
EP2767826A1 (en) * | 2006-10-04 | 2014-08-20 | Dexcom, Inc. | Dual Electrode System For A Continuous Analyte Sensor |
WO2008050145A1 (en) * | 2006-10-27 | 2008-05-02 | Suresensors Ltd | Measurement device |
US12394120B2 (en) | 2007-06-08 | 2025-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US11373347B2 (en) | 2007-06-08 | 2022-06-28 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US9741139B2 (en) | 2007-06-08 | 2017-08-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8562558B2 (en) | 2007-06-08 | 2013-10-22 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US10403012B2 (en) | 2007-06-08 | 2019-09-03 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US9451910B2 (en) | 2007-09-13 | 2016-09-27 | Dexcom, Inc. | Transcutaneous analyte sensor |
US12016648B2 (en) | 2007-09-13 | 2024-06-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9668682B2 (en) | 2007-09-13 | 2017-06-06 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11672422B2 (en) | 2007-09-13 | 2023-06-13 | Dexcom, Inc. | Transcutaneous analyte sensor |
US11160926B1 (en) | 2007-10-09 | 2021-11-02 | Dexcom, Inc. | Pre-connected analyte sensors |
US11744943B2 (en) | 2007-10-09 | 2023-09-05 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US12246166B2 (en) | 2007-10-09 | 2025-03-11 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US10653835B2 (en) | 2007-10-09 | 2020-05-19 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US12397110B2 (en) | 2007-10-09 | 2025-08-26 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US12397113B2 (en) | 2007-10-09 | 2025-08-26 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US9717449B2 (en) | 2007-10-25 | 2017-08-01 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10182751B2 (en) | 2007-10-25 | 2019-01-22 | Dexcom, Inc. | Systems and methods for processing sensor data |
US11272869B2 (en) | 2007-10-25 | 2022-03-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9901307B2 (en) | 2007-12-17 | 2018-02-27 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9339238B2 (en) | 2007-12-17 | 2016-05-17 | Dexcom, Inc. | Systems and methods for processing sensor data |
US11342058B2 (en) | 2007-12-17 | 2022-05-24 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10827980B2 (en) | 2007-12-17 | 2020-11-10 | Dexcom, Inc. | Systems and methods for processing sensor data |
US10506982B2 (en) | 2007-12-17 | 2019-12-17 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9149233B2 (en) | 2007-12-17 | 2015-10-06 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9149234B2 (en) | 2007-12-17 | 2015-10-06 | Dexcom, Inc. | Systems and methods for processing sensor data |
US12165757B2 (en) | 2007-12-17 | 2024-12-10 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9839395B2 (en) | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20090192366A1 (en) * | 2007-12-17 | 2009-07-30 | Dexcom, Inc | Systems and methods for processing sensor data |
US9020572B2 (en) | 2008-02-21 | 2015-04-28 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US20100331656A1 (en) * | 2008-02-21 | 2010-12-30 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US9143569B2 (en) | 2008-02-21 | 2015-09-22 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8229535B2 (en) | 2008-02-21 | 2012-07-24 | Dexcom, Inc. | Systems and methods for blood glucose monitoring and alert delivery |
US8591455B2 (en) | 2008-02-21 | 2013-11-26 | Dexcom, Inc. | Systems and methods for customizing delivery of sensor data |
US20100331657A1 (en) * | 2008-02-21 | 2010-12-30 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US11102306B2 (en) | 2008-02-21 | 2021-08-24 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
US11896374B2 (en) | 2008-03-25 | 2024-02-13 | Dexcom, Inc. | Analyte sensor |
US10602968B2 (en) | 2008-03-25 | 2020-03-31 | Dexcom, Inc. | Analyte sensor |
US20100327886A1 (en) * | 2008-03-27 | 2010-12-30 | Toshifumi Nakamura | Measurement device, measurement system, and concentration measurement method |
US8954128B2 (en) | 2008-03-28 | 2015-02-10 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US20100280341A1 (en) * | 2008-03-28 | 2010-11-04 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US10143410B2 (en) | 2008-03-28 | 2018-12-04 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11147483B2 (en) | 2008-03-28 | 2021-10-19 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9693721B2 (en) | 2008-03-28 | 2017-07-04 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9572523B2 (en) | 2008-03-28 | 2017-02-21 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9566026B2 (en) | 2008-03-28 | 2017-02-14 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9549699B2 (en) | 2008-03-28 | 2017-01-24 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9173607B2 (en) | 2008-03-28 | 2015-11-03 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US20090247856A1 (en) * | 2008-03-28 | 2009-10-01 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US20100096259A1 (en) * | 2008-03-28 | 2010-04-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US9173606B2 (en) | 2008-03-28 | 2015-11-03 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
USD598126S1 (en) * | 2008-06-06 | 2009-08-11 | Lifescan Scotland Limited | Electrochemical test strip |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10561352B2 (en) | 2008-09-19 | 2020-02-18 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10028684B2 (en) | 2008-09-19 | 2018-07-24 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10028683B2 (en) | 2008-09-19 | 2018-07-24 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US11918354B2 (en) | 2008-09-19 | 2024-03-05 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US9339222B2 (en) | 2008-09-19 | 2016-05-17 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
US10980461B2 (en) | 2008-11-07 | 2021-04-20 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US10675405B2 (en) | 2009-03-27 | 2020-06-09 | Dexcom, Inc. | Methods and systems for simulating glucose response to simulated actions |
US9446194B2 (en) | 2009-03-27 | 2016-09-20 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US10537678B2 (en) | 2009-03-27 | 2020-01-21 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US10610642B2 (en) | 2009-03-27 | 2020-04-07 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US20110048972A1 (en) * | 2009-08-31 | 2011-03-03 | Lifescan Scotland Limited | Multi-analyte test strip with shared counter/reference electrode and inline electrode configuration |
US8679310B2 (en) * | 2010-04-22 | 2014-03-25 | Arkray, Inc. | Biosensor |
DE102011007918B4 (en) | 2010-04-22 | 2022-04-14 | Arkray, Inc. | Biosensor, monitor, program and method |
USD703208S1 (en) * | 2012-04-13 | 2014-04-22 | Blackberry Limited | UICC apparatus |
US8936199B2 (en) | 2012-04-13 | 2015-01-20 | Blackberry Limited | UICC apparatus and related methods |
USD702240S1 (en) * | 2012-04-13 | 2014-04-08 | Blackberry Limited | UICC apparatus |
USD701864S1 (en) * | 2012-04-23 | 2014-04-01 | Blackberry Limited | UICC apparatus |
US11706876B2 (en) | 2017-10-24 | 2023-07-18 | Dexcom, Inc. | Pre-connected analyte sensors |
US12150250B2 (en) | 2017-10-24 | 2024-11-19 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
US11943876B2 (en) | 2017-10-24 | 2024-03-26 | Dexcom, Inc. | Pre-connected analyte sensors |
US11350862B2 (en) | 2017-10-24 | 2022-06-07 | Dexcom, Inc. | Pre-connected analyte sensors |
US11382540B2 (en) | 2017-10-24 | 2022-07-12 | Dexcom, Inc. | Pre-connected analyte sensors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050139489A1 (en) | Method of reducing the effect of direct and mediated interference current in an electrochemical test strip | |
US20050109618A1 (en) | Meter for use in an improved method of reducing interferences in an electrochemical sensor using two different applied potentials | |
CN100473983C (en) | Method for reducing the effects of direct interference current in electrochemical test strips | |
KR20070022195A (en) | Electrochemical test strips to reduce the effects of direct interference currents | |
HK1093095B (en) | Electrochemical test strip for reducing the effect of direct interference current | |
HK1091896B (en) | Method of reducing the effect of direct interference current in an electrochemical test strip |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LIFESCAN, SCOTLAND, LTD., UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAVIES, OLIVER WILLIAM HARDWICKE;MARSHALL, ROBERT;BASKEYFIELD, DAMIAN EDWARD HAYDON;AND OTHERS;REEL/FRAME:015811/0600;SIGNING DATES FROM 20041112 TO 20041116 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |